Nebraska 18+ Casinos - NE Online Casinos For 18+ Players

can you gamble in nebraska

can you gamble in nebraska - win

Comprehensive DD on $CTYX: The OTC Biotech Stock of the Decade That Is Being Slept On

[Connectyx (OTC-PINK: CTYX). Will change to Curative Biotechnology with ticker $CURB in Q1 2021.]
I posted this on pennystocks yesterday.
Full Disclosure: I have a $6k initial position in this stock at a cost average of $.06. The stock is now at $0.155 (as of 2/6/21) with my position at $15.5k and movement is just starting.
I am not a financial advisor. I am simply a broke graduate student interested in investing and fucking retiring early. This post represents my personal views and should not be taken as financial advice. Do your own damn research and stop pumping your hard-earned cash into trending stocks on Reddit posts that are nothing but hype, rocket emojis, and a mob chat jerking each other off. Also, not a doctor! The medical content below should never be a substitute for professional medical advice.
With that said, $CTYX is going to fucking Pluto 🚀🚀🚀🚀🚀🚀 🌑
Price Target: $0.5 by May 1, 2021; $1.25 - $3.00 (~10x) within 2 years with credible potential to be listed on NASDAQ.
This company is absolutely solid on all sides: healthy financials, an experienced & reliable management team, favorable market conditions with a reasonable business model, a solid lineup of products in its pipeline, and many large announcements anticipated within the next 3 months. Simply put, there is extreme asymmetric upside.
$CTYX or Connectyx was taken over by its current team led by CEO Paul Michaels around Feb 2020. Within a year, this CEO has kept every promise he's made and established the infrastructure for growth. The company specializes in bringing orphan drugs (more on this below) through clinical trials and then to market. Paul and his team have decades of experience in big pharma, biotech research, finance, and drug licensing/development (in-depth description in the Management Team section below). They've vetted 3 promising drug candidates in under a year and promised to start clinical trials by mid-2022. If any one of these pass phase 1/2 trials, the market cap grows by hundreds of millions. They also have a reasonable chance to obtain a Priority Review Voucher (PRV) from the FDA that is worth $100-$300M from their strategic picks. They have a clean balance sheet, acquired non-dilute bridge financing while putting these drugs through trials, and have plans of additional deals in the near future.
Why orphan drugs? Orphan drugs are therapeutics that treat rare diseases (defined as illnesses affecting less than 200k Americans per year). From the Orphan Drug Act, there are multiple incentives given by the government to develop orphan drugs: (1) significant tax credits (2) longer market exclusivity after approval (3) waiver of certain FDA fees (4) easier & faster approval process. In 2019, the global orphan drug market is estimated to be valued at $151B. By 2027, this is projected to reach $340.84B (10% compounded annual growth). This the cornerstone of their business model. By gathering a group of experts, they can cheaply vet high potential candidates to add to their development pipeline and then commercialize them from reduced fees as well as fast-track benefits from the FDA.
So why the hell is it call Connectyx? It is just the old name of a software services company which the team acquired. The company has filed for a name change that will be granted within the next 2 weeks to Curative Biotechnology Inc. with a new ticker $CURB. In addition, the CEO himself has hinted at an uplisting to $OTCQB (a certification upgrade from current pink sheet status), mergeacquisition announcements, and $100M in non-dilutive funding. The official FINRA announcement of the name change will be the catalyst for the additional news.
Some quick notes about the charts. The 15x jump in the past couple of months is only the beginning. There is a clear trend of resistance breakthroughs and medium-term consolidation after each announcement. Volatility is low, the number of outstanding shares is small, and there is limited dilutive potential for an OTC.
Let's dive deeper into this hidden gem.
All-Star Management Team
CEO Paul Michaels
Curative BioTech lucked out with a CEO with 25 years of experience in investment banking with a focus on life sciences. Paul has an impressive record, starting as the Executive Vice President and board member of Global Capital Group (a Wall Street wealth management firm). He also got extensive experience in big Pharma through Inabata & Co. Ltd, a subsidiary of a large Japanese drug company, Sumitomo Chemical Group, which totaled $21.8B in revenue in 2013 and employs over 30k people. While serving as Inabata's CFO, Paul licensed American drugs (some from Gilead) for the Asian market. After, the guy helped create Nobelpharma, an orphan drug company, which licenses drugs for rare diseases and got over $35M in initial capital.
In February 2020, Paul took over Connectyx (a software services company at the time) and made it an orphan drug company. It is extremely rare for pink-sheet companies to have such high-caliber, established talent as a leader: decades of experience with finance and leadership positions in multi-billion dollar pharmaceutical companies. He helped build up Inabata and Nobelpharam (both thriving today), and I am confident in his ability to do it again with Connectyx.
VP Communications Pam Bisikirski
Recently, Curative announced Pam as the new Vice President of Communications. She previously served as the director of marketing of National Vision for 21 years. National Vision ($EYE) is a huge optical retail, eye care, and eye-ware company that is trading near a $4B market cap on NASDAQ.
Scientific Advisory Board
Dr. Michael Grace [news] - Ph.D. in Biochemistry and BS in Chemistry from the University of Nebraska. 30 years of experience in BioPharma with top roles in names like Procter & Gamble, Schering-Plough, Bristol-Myers Squibb, NPS Pharma, and Advaxis Immunotherapies. Lead 6 products to registration and commercialization.
Dr. Ronald Bordens [news] - Ph.D. in Biotechnology with over 26 publications and over 2000 citations. 40 years in biotech and big pharma in research & development. Had a fruitful 26-year career at Schering-Plough Research.
Richard Garr [news] - Serves as Director and CEO as well as President of Neuralstem Inc. (now Seneca Biopharma, Inc. which is listed on NASDAQ as $SNCA) for 20 years. Advocate for right to try treatments in the US and Europe. Founded Access Hope CRO (contract research organization) which dedicates itself to this cause. Was founder and current Board Member of the First Star Foundation Mid-Atlantic chapter which focuses on ill children (including pediatric brain cancer).
Robust Drug Pipeline
Keep in mind this company became a biotech firm in Feb 2020 and they already have 3 drugs in the pipeline along with exclusive rights licenses. Insane.
1) IMT504 immune therapy to treat late-stage rabies.
(11/23/2020 Announcement implies IMT504 rabies license deal is complete)
Strategic relationship with Mid-Atlantic BioTherapeutics, Inc. announced on 8/27/2020. Acquired all rights for development of this patented immunotherapy to treat late-stage rabies (a disease with 100% fatality rate after the treatable period, [kills 59k](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6613553/#:~:text=about this topic%3F-,Each year%2C rabies causes approximately 59%2C000 deaths worldwide%2C including approximately,of postexposure prophylaxis (PEP).).)) globally per year).
Now, the value of this may not be in the drug approval itself (although passing trials would be a huge asset of course). The value is the potential in CTYX obtaining a Priority Review Voucher (PRV). These coupons are handed out by the FDA each year to incentivize research into rare diseases. Exercising the coupon means diminishing the approval process from 10 months to 6 after trials. Further, you can freely sell these on a secondary market to other companies! Historically, these have been sold between $100M to $300M each. If obtained, this is an instant 2x-6x increase to its current $50M market cap. There's more.. notice that the FDA has added Rabies to its PRV-eligible tropical diseases list. Currently, there is only a handful of rabies therapies being researched. This means there's actually a good chance of CYTX getting rewarded a voucher, despite the relatively low count of vouchers distributed annually. PRVs are also possible for all other drugs in the pipeline.
2) CURB906 monoclonal antibody cytotoxic conjugate for the treatment of Glioblastoma.
(10/16/2020 NIH gives a grant of license for worldwide rights)
The second license was filed near July 2020 for a novel monoclonal antibody conjugate to treat brain cancer. Glioblastomas are aggressive brain tumors with poor survival rates in children. Recent studies (e.g. s1, s2) have shown different combinations of chemo-therapy and antibody-drug conjugate (ADCs) therapeutics were effective in both mice and human models. ADCs are innovative methods that attach a cytotoxic compound (one meant to kill cancer cells) to an antibody that specifically attaches to certain cancer cell receptors, thus delivering therapies to their targets. There is great promise and lots of potential in these therapeutics. Exclusive Evaluation and Commercialization Option License Agreement with the National Cancer Institute (NCI) has been granted.
3) Metformin repurposed to treat retinal degeneration.
(2/4/2021 NIH gives a grant of license for worldwide rights)
This is probably the ace in the hole and the largest reason behind the recent stock surge. On 2/4/2021, CTYX announced they received an NIH grant for exclusive worldwide rights to adapt a diabetes drug, Metformin, to treat retinal degeneration. Not only is Metformin proven safe (it is a widely used drug to treat Type1 Diabetes since 1995), there are many studies (e.g. s1, s2, s3) that hint at its effectiveness for retinal diseases. The recently granted license not only covers pediatric retinal generation (in the form of Stargardt Disease), it covers treatment in adults as well and includes macular degeneration. This promising treatment potentially covers 2/3 of the US population (2/3 of Americans are pre-diabetic, 1/10 are diabetic, and 11 million have some form of macular degeneration; why care about diabetes? diabetes causes retinopathy).
Huge Upcoming Announcements
The announced name change is the opening of the flood gates for all upcoming news. Additional licenses, uplistings, and deals with be done under the new company name. Expect many of these announcements following FINRA approval. These are some forward-looking implications:
  1. (Within 2 weeks) FINRA approval of name change to Curative Biotechnology Inc. and ticker $CURB.
  2. (Within weeks of name change) Following the name change, there will be an uplisting to OTCQB. OTCQB is a tier up from Pink Sheets and must adhere to stricter management certifications, undergo annual audits, and are more stringent in their financial reporting. Connectyx is currently working to become fully reporting OTCQB; to that end, the Company appointed Jonathan D. Leinwand, PA as Legal Counsel.
  3. (Within weeks of name change) Talk of multiple upcoming drugs (if the Metformin announcement was one of them, we should see at least one more).
  4. (Within weeks of name change) Hints at $100M of non-dilutive funding for clinical trials.
  5. (Within months of name change) Mergers, acquisitions, and partnerships with other firms for licensing and commercialization.
Downsides
Before we get ahead of ourselves and dream about retiring in 3 months while riding this into space, we gotta ground ourselves and discuss the downsides. Remember: in life, there are no solutions, only tradeoffs. There are always downsides and risks.
Risk 1) This is currently a pink sheet. That itself should make you more cautious because there is reduced regulation, more "flexible" rules, and less scrutiny/transparency.
Risk 2) High risk, high reward. If all 3 drugs flop (assuming no additional therapeutics are added) and they don't get a PRV (priority review voucher), then this company is worthless. Granted, the chances are low, but still a possibility to consider.
Risk 3) Share dilution and raising capital. Because clinical trials often require obscene amounts of capital (~$400M investment for normal drugs), there is a risk that managers might dilute the stock in order to raise money or to take profits in general. There are currently 322M outstanding shares with 1.1B authorized shares. Read the share disclosures, do the math, gauge the risks. Note that orphan drug trials are a lot less costly as well.
Risks and unknowns are certainly there. However, the upside potential is too big to ignore. Buy at pennies, sell for dollars. Do the research and take advantage of any dips that might come on Monday from 2 days of green explosions.
------------------------------------------------------------
TL;DR.
Resources
Again, these are just my thoughts. For your own research, I've linked some relevant forums, analysis, grant listings, company resources, insider profiles, and other sources. Happy digging.
Company
Company Website (new website coming soon w/ new company name)
Yahoo Finance (has all their press releases, financial summaries, and prospectives)
"Prospective" Grant Listings (all grants listed have been approved)
CTYX Financial Filings
CTYX Share Structure and Security Details
Insider Personel
CEO LinkedIn (Paul M Michaels)
CSO LinkedIn (Barry A. Ginsberg)
VP Communications (Pam Bisikirski)
Chairman of Audit Committee of Board (Michael K. Fish)
Forums / Discussions
https://stocktwits.com/symbol/CTYX (~200 followers right now)
https://investorshub.advfn.com/Connectyx-Techs-Hldg-CTYX-15134/ (warning: UI is god awful)
submitted by charzhar to TheDailyDD [link] [comments]

The Medieval Blood Libel Lives On In QAnon: Child Cannibalism, St William of Norwich, and Abortion

Well, this is going to be a long hot mess, I apologize from the start, like Inigo Montoya I have to say, "There is too much" even trying to sum it up, partly because it's a lot and I mean a LOT of history, also because it's very personal to me. I'm lucky that I don't live with any Qultists, but I deal with it at work, and we all deal with them on some level, as we saw on Jan 6th. I really want to make a joke about a national "Epiphany" but there's just nothing funny about it, even if it has some grotesque comedy.
It's personal because I was raised in a worldview that feeds this, and I feel amazingly lucky, like I was just missed by a meteor by inches, that I got out long enough ago that there was no chance of buy-in. But the whole thing is so triggering for that reason, I have a clear memory of having believed in secret alternate histories full of conspiracism and prophecies, in which every historical event had alternate interpretations explained by Sin, with the greatest sin of all being abortion, where all the media and all of science/medicine was lying to us because they hated God and families and goodness, but we weren't supposed to DO anything but pray because it was part of God's plan (trust the plan!)
So it's like being a fish that has taken to the land, remembering swimming in that sea of delusions, but now breathing air and even trying to recall that mindset feels like drowning today. But it helps explain what is going on and why Q is so potently seductive - it's a very ancient meme that has been constantly refined and tweaked over centuries, with a steroid injection a hundred years ago that took it to all new catastrophic levels culminating in the Holocaust.
That was of course the "Protocols of the Elders of Zion," a propaganda work created in 1903 by the Russian government to retroactively justify their pogroms by supposedly-leaked documents revealing the secret programs by the secret Jewish leadership to subvert and destroy mainstream Christian society, which was translated in 1919 in English and was promoted and published in America by non other than Henry Ford, whose bigotry and open embrace of fascism somehow never made it into our history books when I was in school and he was praised as an American genius-hero, while the theater class was putting on "Fiddler on the Roof. "
They didn't tell us about IBM then, either.
The Protocols memetic influence can be seen in the David Ickes Lizard people secretly rule the world stuff, but it's also invisibly omnipresent in the entire anti-abortion movement. The Protocols didn't appear in an early 20th century vacuum, instead they drew on a long tradition across Europe of justifying persecution of minorities by claiming they were uniquely wicked and depraved so it was really self defense, and particularly targeting their Jewish neighbors with the accusation of ritually killing and eating Christian children. William of Norwich was the first unsolved crime of a murdered boy whose death was blamed on the local Jewish community, in spite of the local government saying it was unproven at the time, but not the last.
Right there, you can see where we are now, in a "distant mirror" to use historian Tuchman's phrase: the accusation wouldn't have been made if there hadn't already been bigotry, which in turn led them to reject the official government statement that persons unknown committed the crime, and an entire fictional account being treated as "the truth" since it didn't have the uncomfortable possibility that it was one of US who did it, and we could be breaking bread with a murderer! No, no, it must have been one of those heretical THEM!
And it never goes away, even if serious respectable people in positions of authority tried to debunk and disprove and defuse the mob mentality - that just proves that they've been turned or bought or are part of the child-sacrificing cult too. The Freemasons get pulled into it, as rivals to the established churches, and eventually abortion too, because Jewish tradition says not a child until born, and the life/health/safety of the mother always took priority. So "Jewish doctors" in pre-WW2 writings where there doesn't seem to be any relevance to a doctor's religion really means abortion, in the censorship of the early 20th century.
And abortion means "good" women running around having sex for fun, with all the fears of being "cucked" that have never left conservative masculinity. "Jews will not replace us" as they chanted at Charlottesville, this "Great Replacement" theory, has it that the secret plan is to use the degenerate arts and media made by (((Hollywood Liberals))) to convince pure white women to race mix, or to not want godly white husbands, so feminism too is part of the plot, and tolerance of gay rights, along with Communism which rebels against the rightful authority of rich white Christian men, whose money means they're blessed by God, unlike the bad people who shouldn't be rich because they're NOT white Christian men, in the horrible hash of memes which fed the rise of the Reich as it had the Tsars' pogroms the last generation.
And so the whole world dealt with the consequences of letting these conspiracies fester and interbreed from the old media of pulpits and bars to the new media of cheap printing, then radio waves, then movie reels. The "blood-dimmed tide" reached everywhere, but that's cold comfort to the victims.
And then the same people who had been preaching the Blood Libel until they got their genocide turned around and cynically applied the term "Holocaust" to legalized abortion. The people who were fans of Fr. Coughlin the "Radio Priest" who did an early Horsehoe Theory going from supporting FDR to supporting Hitler, who rejected Vatican II because it rejected the former ritual blaming "The Jews" for killing poor baby Jesus, and also rejected any and all calls to social justice of every kind.
The Catholic conservatives rebranded by changing "the Jews" to "secular humanists" and "Hollywood liberals" and added "environmentalists" to the long list of child-sacrificers in their conspiracy, and the Fundamentalist conservatives jumped on the bandwagon as a way to erase the stink of supporting segregation and reclaim a moral high ground by protecting innocent babies. Who's more innocent than anyone? The unborn! They've never done anything, so they can't be Milkshake Ducks. (Once they're born? Fuck 'em.)
And YOU don't need to do anything either, just pray and vote Republican! It's so easy! You get to bask in the righteous glow of hating the worst people in the world, people who KILL BABIES for fun & profit, because OBVIOUSLY the doctors are lying when they say pregnancy is dangerous, it's NATURAL, so it must be a highly-profitable industry because otherwise why would they do it? This is straight out of 1930s fascist propaganda, only by 1975 they had so thoroughly erased the word "Jews" that a younger generation never knew it had been there. So there's your distrust of science and medicine and demonization of Planned Parenthood, mandated by Christian religion in far too many churches.
You can boost your conspiracy fix with add-ons like miracles, visions, and secret truths that even the mainstream clergy don't want you to know about, like The Third Secret of Fatima or The Tribulation/The Rapture, or with accusations that not only are the evil (((doctors))) butchering babies for profit and to overthrow Western Civilization, but they're SELLING BABBY PARTS to cosmetics companies and even Coca-Cola.
Why? How would this make sense? Why would companies sneak illegal human tissue into your shampoo or your soda, ffs? Because they're EVIL, duh. Now YOU are part of the ritual cannibalistic cult, like it or not! There are BABBY PARTS in your vaccines, doncha know? You've ALREADY BEEN contaminated! And Procter & Gamble has a Satanic symbol for a logo, and you put their toothpaste IN YOUR MOUTH! How can you care about baby seals when they're murdering baby HUMANS? How can you care about adult workers suffering picking grapes toiling in the vineyards of California or the packing plants of Nebraska when they're killing BABIES? It's a (((Communist)))-Muslim-homo-fascist plot! WE know the TRUTH! The rest of you are either asleep, or supporting the Devil!
At the same time, it's obviously part of the same evil God-hating conspiracy that the media is publishing allegations of priestly pederasty. Disbelieve everyone except us, and hate them because they say WE are the baddies.
No, it's the whole godless nation of America that's evil, because the laws and culture tolerate abortion/gay people/women who take jobs away from men EVEN IN THE ARMY obviously to weaken us so the Commies can roll right over us Wolverines!/tree-huggers who want to replace humans with baby seals and spotted owls/Freemasons/the foreign family who moved in next doothe teens who play loud music and wear weird sexy clothes -- and someday soon, God will smite the land, and THEN you'll all be sorry!
UGH I CAN'T EVEN, I used to believe ALL of this crap and I didn't even get to Paul Weyrich and the Southern Strategy. That will have to be another post, but this is at least a peek through a private window into how "Those who can make you believe absurdities can make you commit atrocities" and we saw the same exact flailing of leaders between running away from the stochastic terror consequences of their words and plunging deeper in when some impressionable young Christians started shooting and blowing up health care providers after having been raised in "Stop the New Holocaust" rhetoric since birth. It was just supposed to motivate you to send us money, vote for the Corporation Party, and do absolutely nothing else except maybe yell at some miserable pregnant people trying to get medical help.
Past is predictive.
All of Q has its roots in the fertile soil of American conspiracism going back to the "Purity of Essence" antifluoride campaigns and the John Birch Society so often mocked but never extinguished, which in turn goes back over a thousand years and even more, because accusing the religious minority you want to scapegoat of being child-sacrificing cannibals worked for the Romans, too.
History is Irony.
Eye-Opening Links - the link between white supremacy and abortion opposition isn't even trying to hide these days, but a decade and more back, it was pretty much only Fred Clark writing as a liberal Christian trying to bring sanity to America by debunking the Rapture peddling reverends of the Right before TEOTWAWKI - "The Biblical View that's Younger than the Happy Meal" is very powerful:
https://www.patheos.com/blogs/slacktivist/2012/02/18/the-biblical-view-thats-younger-than-the-happy-meal/
Here's a Salon article which cites this post, and other authors, on the use of abortion as a way of memoryholing school segregation:
https://www.salon.com/2018/07/08/when-evangelicals-were-pro-choice-and-the-nra-was-pro-gun-control-a-history-of-hypocrisy/
His entire blog, Slacktivist, is worth checking out but it's a lot, so here's just the abortion tag:
https://www.patheos.com/blogs/slacktivist/tag/abortion/
And here's the one that explains why Qult members WANT there to be a vile cult of (((Hollywood liberals))) raping and eating children that they can feel justified in murdering if only by proxy, the saga of Bad Jackie:
https://www.patheos.com/blogs/slacktivist/2010/09/19/jackie-at-the-crossroads/
Here's his post on the Blood Libel propaganda transformation of William of Norwich from tragic victim of an unknown killer into a "martyr" - EXACTLY like Trump using that poor woman shot by accident as a justification to persecute immigrants from the southern border:
https://www.patheos.com/blogs/slacktivist/2019/05/02/thomas-of-monmouth-the-hugely-influential-christian-writer-youve-never-heard-of/
Here's that earlier instance of the alternate reality creation, the Procter & Gamble Satanic fabrication:
https://www.atlasobscura.com/articles/procter-gamble-satan-conspiracy-theory
I don't want to put up links to historic bigoted propaganda, you can find that easily if you really want to, but one thing that's really interesting about the Protocols is that large parts of it were plagiarized from novels and other sources which weren't even about Jews, translated into Russian, and changed to fit the rest of it. That was how the Times of London debunked it in 1921, a lot harder before Turnitin existed. Villainy, but also LAZY villainy, just like we saw the last four years. But it works because the people who ate it up didn't CARE that the fake justification for doing pogroms was a bad pastiche - and they STILL don't.
I'm sorry this is so rough and rambling, but it's like looking into the Mirrorverse and seeing who I could have been if I wasn't too gay, too nerdy and too overall fucked up, when I see those smiling preppy women beating down the Capital doors or posturing on the TV with their guns. The Abyss smirks back winking at me, unrepentant as Sarah Palin at the shooting of Gabby Giffords. I don't know how to get anyone else out of it -- I'm not even sure how I escaped, really!
submitted by PaloVerdePride to QAnonCasualties [link] [comments]

Comprehensive DD on $CTYX: The OTC Biotech Stock of the Decade That Is Being Slept On

[Connectyx (OTC-PINK: CTYX). Will change to Curative Biotechnology with ticker $CURB in Q1 2021.]
Full Disclosure: I have a $6k initial position in this stock at a cost average of $.06. The stock is now at $0.155 (as of 2/6/21) with my position at $15.5k and movement is just starting.
I am not a financial advisor. I am simply a broke graduate student interested in investing and fucking retiring early. This post represents my personal views and should not be taken as financial advice. Do your own damn research and stop pumping your hard-earned cash into trending stocks on Reddit posts that are nothing but hype, rocket emojis, and a mob chat jerking each other off. Also, not a doctor! The medical content below should never be a substitute for professional medical advice.
With that said, $CTYX is going to fucking Pluto 🚀🚀🚀🚀🚀🚀 🌑
Price Target: $0.5 by May 1, 2021; $1.25 - $3.00 (~10x) within 2 years with credible potential to be listed on NASDAQ.
This company is absolutely solid on all sides: healthy financials, an experienced & reliable management team, favorable market conditions with a reasonable business model, a solid lineup of products in its pipeline, and many large announcements anticipated within the next 3 months. Simply put, there is extreme asymmetric upside.
$CTYX or Connectyx was taken over by its current team led by CEO Paul Michaels around Feb 2020. Within a year, this CEO has kept every promise he's made and established the infrastructure for growth. The company specializes in bringing orphan drugs (more on this below) through clinical trials and then to market. Paul and his team have decades of experience in big pharma, biotech research, finance, and drug licensing/development (in-depth description in the Management Team section below). They've vetted 3 promising drug candidates in under a year and promised to start clinical trials by mid-2022. If any one of these pass phase 1/2 trials, the market cap grows by hundreds of millions. They also have a reasonable chance to obtain a Priority Review Voucher (PRV) from the FDA that is worth $100-$300M from their strategic picks. They have a clean balance sheet, acquired non-dilute bridge financing while putting these drugs through trials, and have plans of additional deals in the near future.
Why orphan drugs? Orphan drugs are therapeutics that treat rare diseases (defined as illnesses affecting less than 200k Americans per year). From the [Orphan Drug Act](https://www.wikiwand.com/en/Orphan_Drug_Act_of_1983#:~:text=The Orphan Drug Act of,residing in the United States.)), there are multiple incentives given by the government to develop orphan drugs: (1) significant tax credits (2) longer market exclusivity after approval (3) waiver of certain FDA fees (4) easier & faster approval process. In 2019, the global orphan drug market is estimated to be valued at $151B. By 2027, this is projected to reach $340.84B (10% compounded annual growth). This the cornerstone of their business model. By gathering a group of experts, they can cheaply vet high potential candidates to add to their development pipeline and then commercialize them from reduced fees as well as fast-track benefits from the FDA.
So why the hell is it call Connectyx? It is just the old name of a software services company which the team acquired. The company has filed for a name change that will be granted within the next 2 weeks to Curative Biotechnology Inc. with a new ticker $CURB. In addition, the CEO himself has hinted at an uplisting to $OTCQB (a certification upgrade from current pink sheet status), mergeacquisition announcements, and $100M in non-dilutive funding. The official FINRA announcement of the name change will be the catalyst for the additional news.
Some quick notes about the charts. The 15x jump in the past couple of months is only the beginning. There is a clear trend of resistance breakthroughs and medium-term consolidation after each announcement. Volatility is low, the number of outstanding shares is small, and there is limited dilutive potential for an OTC.
Let's dive deeper into this hidden gem.

All-Star Management Team

CEO Paul Michaels
Curative BioTech lucked out with a CEO with 25 years of experience in investment banking with a focus on life sciences. Paul has an impressive record, starting as the Executive Vice President and board member of Global Capital Group (a Wall Street wealth management firm). He also got extensive experience in big Pharma through [Inabata & Co. Ltd's](https://www.wikiwand.com/en/Inabata_%26_Co.,_Ltd.)), a subsidiary of a large Japanese drug company, Sumitomo Chemical Group, which totaled $21.8B in revenue in 2013 and employs over 30k people. While serving as Inabata's CFO, Paul licensed American drugs (some from Gilead) for the Asian market. After, the guy helped create Nobelpharma, an orphan drug company, which licenses drugs for rare diseases and got over $35M in initial capital.
In February 2020, Paul took over Connectyx (a software services company at the time) and made it an orphan drug company. It is extremely rare for pink-sheet companies to have such high-caliber, established talent as a leader: decades of experience with finance and leadership positions in multi-billion dollar pharmaceutical companies. He helped build up Inabata and Nobelpharam (both thriving today), and I am confident in his ability to do it again with Connectyx.
VP Communications Pam Bisikirski
Recently, Curative announced Pam as the new Vice President of Communications. She previously served as the director of marketing of National Vision for 21 years. National Vision ($EYE) is a huge optical retail, eye care, and eye-ware company that is trading near a $4B market cap on NASDAQ.
Scientific Advisory Board
Dr. Michael Grace [news] - Ph.D. in Biochemistry and BS in Chemistry from the University of Nebraska. 30 years of experience in BioPharma with top roles in names like Procter & Gamble, Schering-Plough, Bristol-Myers Squibb, NPS Pharma, and Advaxis Immunotherapies. Lead 6 products to registration and commercialization.
Dr. Ronald Bordens [news] - Ph.D. in Biotechnology with over 26 publications and over 2000 citations. 40 years in biotech and big pharma in research & development. Had a fruitful 26-year career at Schering-Plough Research.
Richard Garr [news] - Serves as Director and CEO as well as President of Neuralstem Inc. (now Seneca Biopharma, Inc. which is listed on NASDAQ as $SNCA) for 20 years. Advocate for right to try treatments in the US and Europe. Founded Access Hope CRO (contract research organization) which dedicates itself to this cause. Was founder and current Board Member of the First Star Foundation Mid-Atlantic chapter which focuses on ill children (including pediatric brain cancer).

Robust Drug Pipeline

Keep in mind this company became a biotech firm in Feb 2020 and they already have 3 drugs in the pipeline along with exclusive rights licenses. Insane.
1) IMT504 immune therapy to treat late-stage rabies.
(11/23/2020 Announcement implies IMT504 rabies license deal is complete)
Strategic relationship with Mid-Atlantic BioTherapeutics, Inc. announced on 8/27/2020. Acquired all rights for development of this patented immunotherapy to treat late-stage rabies (a disease with 100% fatality rate after the treatable period, [kills 59k](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6613553/#:~:text=about this topic%3F-,Each year%2C rabies causes approximately 59%2C000 deaths worldwide%2C including approximately,of postexposure prophylaxis (PEP).).)) globally per year).
Now, the value of this may not be in the drug approval itself (although passing trials would be a huge asset of course). The value is the potential in CTYX obtaining a Priority Review Voucher (PRV). These coupons are handed out by the FDA each year to incentivize research into rare diseases. Exercising the coupon means diminishing the approval process from 10 months to 6 after trials. Further, you can freely sell these on a secondary market to other companies! Historically, these have been sold between $100M to $300M each. If obtained, this is an instant 2x-6x increase to its current $50M market cap. There's more.. notice that the FDA has added Rabies to its PRV-eligible tropical diseases list. Currently, there is only a handful of rabies therapies being researched. This means there's actually a good chance of CYTX getting rewarded a voucher, despite the relatively low count of vouchers distributed annually. PRVs are also possible for all other drugs in the pipeline.
2) CURB906 monoclonal antibody cytotoxic conjugate for the treatment of Glioblastoma.
(10/16/2020 NIH gives a grant of license for worldwide rights)
The second license was filed near July 2020 for a novel monoclonal antibody conjugate to treat brain cancer. Glioblastomas are aggressive brain tumors with poor survival rates in children. Recent studies (e.g. s1, s2) have shown different combinations of chemo-therapy and antibody-drug conjugate (ADCs) therapeutics were effective in both mice and human models. ADCs are innovative methods that attach a cytotoxic compound (one meant to kill cancer cells) to an antibody that specifically attaches to certain cancer cell receptors, thus delivering therapies to their targets. There is great promise and lots of potential in these therapeutics. Exclusive Evaluation and Commercialization Option License Agreement with the National Cancer Institute (NCI) has been granted.
3) Metformin repurposed to treat retinal degeneration.
(2/4/2021 NIH gives a grant of license for worldwide rights)
This is probably the ace in the hole and the largest reason behind the recent stock surge. On 2/4/2021, CTYX announced they received an NIH grant for exclusive worldwide rights to adapt a diabetes drug, Metformin, to treat retinal degeneration. Not only is Metformin proven safe (it is a widely used drug to treat Type1 Diabetes since 1995), there are many studies (e.g. s1, s2, s3) that hint at its effectiveness for retinal diseases. The recently granted license not only covers pediatric retinal generation (in the form of Stargardt Disease), it covers treatment in adults as well and includes macular degeneration. This promising treatment potentially covers 2/3 of the US population (2/3 of Americans are pre-diabetic, 1/10 are diabetic, and 11 million have some form of macular degeneration; why care about diabetes? diabetes causes retinopathy).

Huge Upcoming Announcements

The announced name change is the opening of the flood gates for all upcoming news. Additional licenses, uplistings, and deals with be done under the new company name. Expect many of these announcements following FINRA approval. These are some forward-looking implications:
​
  1. (Within 2 weeks) FINRA approval of name change to Curative Biotechnology Inc. and ticker $CURB.
  2. (Within weeks of name change) Following the name change, there will be an uplisting to OTCQB. OTCQB is a tier up from Pink Sheets and must adhere to stricter management certifications, undergo annual audits, and are more stringent in their financial reporting. Connectyx is currently working to become fully reporting OTCQB; to that end, the Company appointed Jonathan D. Leinwand, PA as Legal Counsel.
  3. (Within weeks of name change) Talk of multiple upcoming drugs (if the Metformin announcement was one of them, we should see at least one more).
  4. (Within weeks of name change) Hints at $100M of non-dilutive funding for clinical trials.
  5. (Within months of name change) Mergers, acquisitions, and partnerships with other firms for licensing and commercialization.

Downsides

Before we get ahead of ourselves and dream about retiring in 3 months while riding this into space, we gotta ground ourselves and discuss the downsides. Remember: in life, there are no solutions, only tradeoffs. There are always downsides and risks.
Risk 1) This is currently a pink sheet. That itself should make you more cautious because there is reduced regulation, more "flexible" rules, and less scrutiny/transparency.
Risk 2) High risk, high reward. If all 3 drugs flop (assuming no additional therapeutics are added) and they don't get a PRV (priority review voucher), then this company is worthless. Granted, the chances are low, but still a possibility to consider.
Risk 3) Share dilution and raising capital. Because clinical trials often require obscene amounts of capital (~$400M investment for normal drugs), there is a risk that managers might dilute the stock in order to raise money or to take profits in general. There are currently 322M outstanding shares with 1.1B authorized shares. Read the share disclosures, do the math, gauge the risks. Note that orphan drug trials are a lot less costly as well.
Risks and unknowns are certainly there. However, the upside potential is too big to ignore. Buy at pennies, sell for dollars. Do the research and take advantage of any dips that might come on Monday from 2 days of green explosions.
​
------------------------------------------------------------
TL;DR.
​

Resources

Again, these are just my thoughts. For your own research, I've linked some relevant forums, analysis, grant listings, company resources, insider profiles, and other sources. Happy digging.
Company
Company Website (new website coming soon w/ new company name)
Yahoo Finance (has all their press releases, financial summaries, and prospectives)
"Prospective" Grant Listings (all grants listed have been approved)
CTYX Financial Filings
CTYX Share Structure and Security Details
Insider Personel
CEO LinkedIn (Paul M Michaels)
CSO LinkedIn (Barry A. Ginsberg)
VP Communications (Pam Bisikirski)
Chairman of Audit Committee of Board (Michael K. Fish)
Forums / Discussions
https://stocktwits.com/symbol/CTYX (~200 followers right now)
https://investorshub.advfn.com/Connectyx-Techs-Hldg-CTYX-15134/ (warning: UI is god awful)
submitted by charzhar to pennystocks [link] [comments]

Comprehensive DD on $CTYX: The OTC Biotech Stock of the Decade That Is Being Slept On

[Connectyx (OTC-PINK: CTYX). Will change to Curative Biotechnology with ticker $CURB in Q1 2021.]
Full Disclosure: I have a $6k initial position in this stock at a cost average of $.06. The stock is now at $0.155 (as of 2/6/21) with my position at $15.5k and movement is just starting.
I am not a financial advisor. I am simply a broke graduate student interested in investing and fucking retiring early. This post represents my personal views and should not be taken as financial advice. Do your own damn research and stop pumping your hard-earned cash into trending stocks on Reddit posts that are nothing but hype, rocket emojis, and a mob chat jerking each other off. Also, not a doctor! The medical content below should never be a substitute for professional medical advice.
With that said, $CTYX is going to fucking Pluto 🚀🚀🚀🚀🚀🚀 🌑
Price Target: $0.5 by May 1, 2021; $1.25 - $3.00 (~10x) within 2 years with credible potential to be listed on NASDAQ.
This company is absolutely solid on all sides: healthy financials, an experienced & reliable management team, favorable market conditions with a reasonable business model, a solid lineup of products in its pipeline, and many large announcements anticipated within the next 3 months. Simply put, there is extreme asymmetric upside.
$CTYX or Connectyx was taken over by its current team led by CEO Paul Michaels around Feb 2020. Within a year, this CEO has kept every promise he's made and established the infrastructure for growth. The company specializes in bringing orphan drugs (more on this below) through clinical trials and then to market. Paul and his team have decades of experience in big pharma, biotech research, finance, and drug licensing/development (in-depth description in the Management Team section below). They've vetted 3 promising drug candidates in under a year and promised to start clinical trials by mid-2022. If any one of these pass phase 1/2 trials, the market cap grows by hundreds of millions. They also have a reasonable chance to obtain a Priority Review Voucher (PRV) from the FDA that is worth $100-$300M from their strategic picks. They have a clean balance sheet, acquired non-dilute bridge financing while putting these drugs through trials, and have plans of additional deals in the near future.
Why orphan drugs? Orphan drugs are therapeutics that treat rare diseases (defined as illnesses affecting less than 200k Americans per year). From the [Orphan Drug Act](https://www.wikiwand.com/en/Orphan_Drug_Act_of_1983#:~:text=The Orphan Drug Act of,residing in the United States.)), there are multiple incentives given by the government to develop orphan drugs: (1) significant tax credits (2) longer market exclusivity after approval (3) waiver of certain FDA fees (4) easier & faster approval process. In 2019, the global orphan drug market is estimated to be valued at $151B. By 2027, this is projected to reach $340.84B (10% compounded annual growth). This the cornerstone of their business model. By gathering a group of experts, they can cheaply vet high potential candidates to add to their development pipeline and then commercialize them from reduced fees as well as fast-track benefits from the FDA.
So why the hell is it call Connectyx? It is just the old name of a software services company which the team acquired. The company has filed for a name change that will be granted within the next 2 weeks to Curative Biotechnology Inc. with a new ticker $CURB. In addition, the CEO himself has hinted at an uplisting to $OTCQB (a certification upgrade from current pink sheet status), mergeacquisition announcements, and $100M in non-dilutive funding. The official FINRA announcement of the name change will be the catalyst for the additional news.
Some quick notes about the charts. The 15x jump in the past couple of months is only the beginning. There is a clear trend of resistance breakthroughs and medium-term consolidation after each announcement. Volatility is low, the number of outstanding shares is small, and there is limited dilutive potential for an OTC.
Let's dive deeper into this hidden gem.
All-Star Management Team
CEO Paul Michaels
Curative BioTech lucked out with a CEO with 25 years of experience in investment banking with a focus on life sciences. Paul has an impressive record, starting as the Executive Vice President and board member of Global Capital Group (a Wall Street wealth management firm). He also got extensive experience in big Pharma through [Inabata & Co. Ltd's](https://www.wikiwand.com/en/Inabata_%26_Co.,_Ltd.)), a subsidiary of a large Japanese drug company, Sumitomo Chemical Group, which totaled $21.8B in revenue in 2013 and employs over 30k people. While serving as Inabata's CFO, Paul licensed American drugs (some from Gilead) for the Asian market. After, the guy helped create Nobelpharma, an orphan drug company, which licenses drugs for rare diseases and got over $35M in initial capital.
In February 2020, Paul took over Connectyx (a software services company at the time) and made it an orphan drug company. It is extremely rare for pink-sheet companies to have such high-caliber, established talent as a leader: decades of experience with finance and leadership positions in multi-billion dollar pharmaceutical companies. He helped build up Inabata and Nobelpharam (both thriving today), and I am confident in his ability to do it again with Connectyx.
VP Communications Pam Bisikirski
Recently, Curative announced Pam as the new Vice President of Communications. She previously served as the director of marketing of National Vision for 21 years. National Vision ($EYE) is a huge optical retail, eye care, and eye-ware company that is trading near a $4B market cap on NASDAQ.
Scientific Advisory Board
Dr. Michael Grace [news] - Ph.D. in Biochemistry and BS in Chemistry from the University of Nebraska. 30 years of experience in BioPharma with top roles in names like Procter & Gamble, Schering-Plough, Bristol-Myers Squibb, NPS Pharma, and Advaxis Immunotherapies. Lead 6 products to registration and commercialization.
Dr. Ronald Bordens [news] - Ph.D. in Biotechnology with over 26 publications and over 2000 citations. 40 years in biotech and big pharma in research & development. Had a fruitful 26-year career at Schering-Plough Research.
Richard Garr [news] - Serves as Director and CEO as well as President of Neuralstem Inc. (now Seneca Biopharma, Inc. which is listed on NASDAQ as $SNCA) for 20 years. Advocate for right to try treatments in the US and Europe. Founded Access Hope CRO (contract research organization) which dedicates itself to this cause. Was founder and current Board Member of the First Star Foundation Mid-Atlantic chapter which focuses on ill children (including pediatric brain cancer).
Robust Drug Pipeline
Keep in mind this company became a biotech firm in Feb 2020 and they already have 3 drugs in the pipeline along with exclusive rights licenses. Insane.
1) IMT504 immune therapy to treat late-stage rabies.
(11/23/2020 Announcement implies IMT504 rabies license deal is complete)
Strategic relationship with Mid-Atlantic BioTherapeutics, Inc. announced on 8/27/2020. Acquired all rights for development of this patented immunotherapy to treat late-stage rabies (a disease with 100% fatality rate after the treatable period, [kills 59k](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6613553/#:~:text=about this topic%3F-,Each year%2C rabies causes approximately 59%2C000 deaths worldwide%2C including approximately,of postexposure prophylaxis (PEP).).)) globally per year).
Now, the value of this may not be in the drug approval itself (although passing trials would be a huge asset of course). The value is the potential in CTYX obtaining a Priority Review Voucher (PRV). These coupons are handed out by the FDA each year to incentivize research into rare diseases. Exercising the coupon means diminishing the approval process from 10 months to 6 after trials. Further, you can freely sell these on a secondary market to other companies! Historically, these have been sold between $100M to $300M each. If obtained, this is an instant 2x-6x increase to its current $50M market cap. There's more.. notice that the FDA has added Rabies to its PRV-eligible tropical diseases list. Currently, there is only a handful of rabies therapies being researched. This means there's actually a good chance of CYTX getting rewarded a voucher, despite the relatively low count of vouchers distributed annually. PRVs are also possible for all other drugs in the pipeline.
2) CURB906 monoclonal antibody cytotoxic conjugate for the treatment of Glioblastoma.
(10/16/2020 NIH gives a grant of license for worldwide rights)
The second license was filed near July 2020 for a novel monoclonal antibody conjugate to treat brain cancer. Glioblastomas are aggressive brain tumors with poor survival rates in children. Recent studies (e.g. s1, s2) have shown different combinations of chemo-therapy and antibody-drug conjugate (ADCs) therapeutics were effective in both mice and human models. ADCs are innovative methods that attach a cytotoxic compound (one meant to kill cancer cells) to an antibody that specifically attaches to certain cancer cell receptors, thus delivering therapies to their targets. There is great promise and lots of potential in these therapeutics. Exclusive Evaluation and Commercialization Option License Agreement with the National Cancer Institute (NCI) has been granted.
3) Metformin repurposed to treat retinal degeneration.
(2/4/2021 NIH gives a grant of license for worldwide rights)
This is probably the ace in the hole and the largest reason behind the recent stock surge. On 2/4/2021, CTYX announced they received an NIH grant for exclusive worldwide rights to adapt a diabetes drug, Metformin, to treat retinal degeneration. Not only is Metformin proven safe (it is a widely used drug to treat Type1 Diabetes since 1995), there are many studies (e.g. s1, s2, s3) that hint at its effectiveness for retinal diseases. The recently granted license not only covers pediatric retinal generation (in the form of Stargardt Disease), it covers treatment in adults as well and includes macular degeneration. This promising treatment potentially covers 2/3 of the US population (2/3 of Americans are pre-diabetic, 1/10 are diabetic, and 11 million have some form of macular degeneration; why care about diabetes? diabetes causes retinopathy).
Huge Upcoming Announcements
The announced name change is the opening of the flood gates for all upcoming news. Additional licenses, uplistings, and deals with be done under the new company name. Expect many of these announcements following FINRA approval. These are some forward-looking implications:
  1. (Within 2 weeks) FINRA approval of name change to Curative Biotechnology Inc. and ticker $CURB.
  2. (Within weeks of name change) Following the name change, there will be an uplisting to OTCQB. OTCQB is a tier up from Pink Sheets and must adhere to stricter management certifications, undergo annual audits, and are more stringent in their financial reporting. Connectyx is currently working to become fully reporting OTCQB; to that end, the Company appointed Jonathan D. Leinwand, PA as Legal Counsel.
  3. (Within weeks of name change) Talk of multiple upcoming drugs (if the Metformin announcement was one of them, we should see at least one more).
  4. (Within weeks of name change) Hints at $100M of non-dilutive funding for clinical trials.
  5. (Within months of name change) Mergers, acquisitions, and partnerships with other firms for licensing and commercialization.
Downsides
Before we get ahead of ourselves and dream about retiring in 3 months while riding this into space, we gotta ground ourselves and discuss the downsides. Remember: in life, there are no solutions, only tradeoffs. There are always downsides and risks.
Risk 1) This is currently a pink sheet. That itself should make you more cautious because there is reduced regulation, more "flexible" rules, and less scrutiny/transparency.
Risk 2) High risk, high reward. If all 3 drugs flop (assuming no additional therapeutics are added) and they don't get a PRV (priority review voucher), then this company is worthless. Granted, the chances are low, but still a possibility to consider.
Risk 3) Share dilution and raising capital. Because clinical trials often require obscene amounts of capital (~$400M investment for normal drugs), there is a risk that managers might dilute the stock in order to raise money or to take profits in general. There are currently 322M outstanding shares with 1.1B authorized shares. Read the share disclosures, do the math, gauge the risks. Note that orphan drug trials are a lot less costly as well.
Risks and unknowns are certainly there. However, the upside potential is too big to ignore. Buy at pennies, sell for dollars. Do the research and take advantage of any dips that might come on Monday from 2 days of green explosions.
------------------------------------------------------------
TL;DR.
Resources
Again, these are just my thoughts. For your own research, I've linked some relevant forums, analysis, grant listings, company resources, insider profiles, and other sources. Happy digging.
Company
Company Website (new website coming soon w/ new company name)
Yahoo Finance (has all their press releases, financial summaries, and prospectives)
"Prospective" Grant Listings (all grants listed have been approved)
CTYX Financial Filings
CTYX Share Structure and Security Details
Insider Personel
CEO LinkedIn (Paul M Michaels)
CSO LinkedIn (Barry A. Ginsberg)
VP Communications (Pam Bisikirski)
Chairman of Audit Committee of Board (Michael K. Fish)
Forums / Discussions
https://stocktwits.com/symbol/CTYX (~200 followers right now)
https://investorshub.advfn.com/Connectyx-Techs-Hldg-CTYX-15134/ (warning: UI is god awful)
submitted by charzhar to investing [link] [comments]

Looking to the Future: 2021 Offensive Staff and Players

On Paper the 2021 Florida team is going to be stacked with talent. However most of our players but will either be really inexperienced or have played sparingly in 2020. Pair that with an above average schedule, a new QB, and potentially new additions to the coaching staff and this could be more of a reloading/rebuilding season. It bodes well for sustained long term success though because I believe even with all those factors that our team will be extremely competitive next season and I would predict at least 9 wins next year.
In this feature I will provide a brief breakdown of every position group and my projected depth chart. I have made some minor changes from my initial posts to now and those will be noted. I also have the coaches listed this time.

2021 QB ROSTER

Name Year Height/Weight 24/7 Rating
Emory Jones R-Jr 6’2 / 220 4 Star (.9587)
Anthony Richardson R-Fr 6’4 / 234 4 Star (.9204)
Carlos Del Rio Fr 6’4 / 220 4 Star (.9357)
Jalen Kitna Fr 6’4 / 215 3 Star (.8683)
Coach Chances of Leaving Potential Replacements
Brian Johnson 70% Kerwin Bell (UF OA), Scott Frost (NE HC), Connor Shaw (SC QB)
Potential Replacements

2021 RB Roster

Name Year Height/Weight 24/7 Rating
Lorenzo Lingard R-Jr 6.0 / 203 5 Star (.9861)
Nay’Quan Wright R-So 5’9 / 195 4 Star (.9061)
Demarkus Bowman R-Fr 5’10 / 190 5 Star (.9909)
Charles Montgomery Fr 5’10 / 185 4 Star (.9082)
Coach Chances of Leaving Potential Replacements
Greg Knox 0% None
  • Greg Knox - Knox is super close to Mullen and wont be leaving anytime soon. He is a solid coach and his only real flaw is recruting but if we can land 5 Star transfers every year in the portal and he can develop them like Pierce, Wright and Davis then I hope he sticks around for a long time.

2021 WR Roster

Name Year Height/Weight 24/7 Rating
Jordan Pouncey R-Sr 6’1 / 215 3 Star (.8540)
Justin Shorter R-Jr 6’5 / 225 5 Star (.9962)
Jacob Copeland* R-Jr 6’0 / 203 4 Star (.9651)
Ja’Markis Weston R-So 6’4 / 215 3 Star (.8763)
Trent Whittemore R-So 6’4 / 210 3 Star (.8643)
Xzavier Henderson So 6’4 / 191 4 Star (.9700)
Ja’Quavion Fraziars R-Fr 6’4 / 211 4 Star (.9317)
Trevonte Rucker Fr 5’11 / 160 4 Star (.9225)
Daejon Reynolds Fr 6’2 / 210 4 Star (.9161)
Marcus Burke Fr 6’3 / 180 4 Star (.9148)
* Note I had Copeland transferring initially in my original writeup. I think he comes back now.
Coach Chances of Leaving Potential Replacements
Billy Gonzalez 20% None
  • Billy Gonzalez - Gonzalez like Knox is super close to Mullen. However unlike Knox I think he might have HC asperations one day. So I wont put his chances of leaving at 0% but its not high enough for me to consider any replacements right now.

2021 TE Roster

Name Year Height/Weight 24/7 Rating
Kemore Gamble R-Sr 6’4 / 248 4 Star (.8987)
Keon Zipperer Jr 6’2 / 240 4 Star (.9548)
Jonathan Odom R-Fr 6’5 / 238 3 Star (.8643)
Gage Wilcox Fr 6’5 / 228 4 Star (.8990)
Nick Elksnis Fr 6’6 / 220 3 Star (.8876)
Coach Chances of Leaving Potential Replacements
Tim Brewster 20% None
  • Tim Brewster - He is a well known recruiting mercenary but he has stated he wants to be here for a long time and Dan gave him the AHC role. Like Gonzalez I wont put his chances of leaving at 0% but they are not high enough for me to consider replacements right now.

2021 OL Roster

Name Year Height/Weight 24/7 Rating
Griffin McDowell R-Jr 6’5 / 300 3 Star (.8342)
Richard Gouraige R-Jr 6’5 / 316 4 Star (.9603)
Ethan White Jr 6’5 / 335 3 Star (.8643)
Riley Simonds R-So 6’4 / 303 3 Star (.8809)
Kingsley Eguakun R-So 6’4 / 322 3 Star (.8689)
Michael Tarquin R-So 6’5 / 312 4 Star (.9041)
Will Harrod R-So 6’5 / 330 4 Star (.8904)
Josh Braun So 6’6 / 340 4 Star (.9049)
Gerald Mincey R-Fr 6’6 / 337 3 Star (.8681)
Richie Leonard R-Fr 6’2 / 347 3 Star (.8633)
Mark Pitts* R-Fr 6’6 / 313 3 Star (.8390)
Yoursef Mugharbil Fr 6’5 / 304 4 Star (.9059)
Javonte Gardner Fr 6’5 / 290 3 Star (.8816)
Deyavie Hammond Fr 6’4 / 330 3 Star (.8739)
Jake Slaughter Fr 6’4 / 300 3 Star (.8654)
Adrein Strickland Fr 6’6 / 330 3 Star (.8431)
Coach Chances of Leaving Potential Replacements
John Hevesy 0% None
  • John Hevesy - Hevesy is attached to Dan Mullens hip and will stick with Dan until Dan either fires him (unlikely) or John retires.

PROJECTED OFFENSIVE DEPTH CHART

Returning Starters in Bold
Position Starter Backup Rotation
QB Emory Jones R-Jr Anthony Richardson R-Fr Carlos Del Rio Fr
RB Nay’Quan Wright R-So Demarkus Bowman R-Fr Lorenzo Lingard R-Jr
WR-X Justin Shorter R-Jr Ja’Quavion Fraziars R-Fr Ja’Markis Weston R-So
WR-Y Jacob Copeland R-Jr Trent Whittemore R-So Jordan Pouncey R-Sr
WR-Z Xzavier Henderson So Marcus Burke Fr Daejon Reynolds Fr
TE Kemore Gamble R-Sr Keon Zipperer Jr Jonathan Odom R-Fr
LT Richard Gouraige R-Jr Will Harrod R-So Yoursef Mugharbil Fr
LG Ethan White Jr Riley Simonds R- So Gerald Mincey R-Fr
C Kingsley Eguakun R-So Richie Leonard R-Fr Jake Slaughter Fr
RG Josh Braun So Griffin McDowell R-Jr Deyavie Hammond Fr
RT Michael Tarquin R-So Mark Pitts R-Fr Yoursef Mugharbil Fr
submitted by thehammersuit to FloridaGators [link] [comments]

Yet another Doordash advice guide! Midwest edition

So this is something I wrote for my friends and I didn't really plan on posting this but a couple of people asked me for my little guide. Keep in mind I live in a town with a population of 250,000 people. not a major metropolis but also not a small town. I highly doubt this advice would be good in 1 million+ population cities at all, but where I live your bigger tips tend to be 5-10$ 5 is average, 10 is rarer and 20 won't happen more than a handful of times a week.
I have worked in two different markets one year in Colorado in one in Nebraska, besides the way traffic flows things are essentially the same, I actually made my reddit account just to be able to post on this subreddit hence the name DasherCO
HOW PAY WORKS
Doordash offers you 3 dollars per delivery. So if you get an offer for 3$ that means thats all you will get from that order, a customer theoretically could prefer tipping in cash but I can tell you out of 3000 deliveries I've gotten MAYBE 50 cash tips. Do not rely on that!
door dash offers 3$=no tip 4$=1 dollar tip 5$=2 dollar tip etc But once you get to 7.50$ thats when they stop showing you the full amount you'll get. Normally this goes up to 8 or 9$. Now if the order is huge it may go up quite a bit more. These are the orders you want to try holding out for if it is super busy. Don't waste time with low offers. The amount may be different in your market so pay attention.
If however doordash is offering a bonus per delivery that amount will go up so for example if doordash is offering 3$ extra per order then your offers go like this
6$=no tip 7$=1 dollar tip 10.50$=4.50 or higher tip
If accepting orders gradually got you to a worse and worse location so you could maintain a good hourly rate and you see a high mileage offer that has an uneven number on it 9 times out of ten that means a big tip.
Example: if the offer is for 13.92 and you have to go 7+miles you can usually expect a 10-20 dollar tip, if its 8.71 and 7+miles it gets smaller but usually its a 7-10$ tip. If it gets you back to where you want to be, generally it's worth it. This is only if good orders keep slingshotting you away from the usual hot zone. However keep in mind if its 7.61 or something that is not going to be a high tip. I have learned all of this through trial and error just because I like knowing what I'm getting myself into with orders that are essentially a gamble.
Also these are not taking into account peak pay so if you have peak pay make sure you take that into account, one time I got fooled by a 11.87 offer because it was 2.50 peak pay, base pay ended up being 6.50. Another thing to note is that if an order has a pickup time that seems unusually tight or is literally before you could have reasonably got there that means its been declined to hell and back and is probably garbage.
GENERAL DAY TO DAY ADVICE
People on the doordash reddit will say don't accept Walmart orders. This is generally a good plan, but not if you work in the morning. If you work in the morning Walmart is your cash cow. The problem with Walmart is they don't let you see who tipped, you know about it 24 hours later. The good thing about Walmart is they suggest the customer tips 7$. This is kinda new, but it has been effective. I have gotten a lot of 7$ tips the next day from Walmart orders at roughly a 6/10 rate compared to the old days where 1 out of 10 people would tip.
Try your best to take 2 Walmart orders at a time, the base offer for Walmart orders is 4$ so potentially each order is worth 11$ and each double is a potential 22$. If the order is unreasonably gigantic you can always unassign and leave. Don't take those 5 pallets of bottled water.
You want the small Walmart orders in the morning that wont take much time. But not so small that they wont tip. something that takes one trip but you gotta load your arms up to get to their door.
But never ever EVER take a Walmart order that will put you in danger of missing out on any part of lunch rush. That is never a good idea and will most likely cost you in the grand scheme of things. If lunch starts in 30 minutes, decline every Walmart order you get. They will never come close to the speed of food orders.
Don't be a dick to most merchants, some just genuinely take time or have bad days, but if it becomes a regular thing then either stop taking orders from them or be assertive so they either move faster or blacklist you.
SHIT THAT HELPS WITH THE JOB
The only thing I can honestly recommend paying your own money for is a drink carrier, it's 13 dollars from doordash and it's super fucking useful for carrying orders with more than 2 drinks up stairs. It's high quality and durable and if you do something like Jimmy john's as well it's a must.
https://doordashstore.com/product.aspx?ID=514297
A pizza bag is super fucking useful but not something I'd pay for personally, I got mine for free but it's nowhere near as important as the drink carrier. Still it will make customers feel better and rate you higher so that's up to you, you can get one for 12 bucks on that same site but get the caviar branded one its 12 bucks, vs doordash's 26 dollar one. The one thing I can't tell you is if the caviar one is good quality I know the DD one is because I have one.
There is also options online for buying stuff like this you can do, check out amazon and other such places it may be cheaper. I just use doordash brand stuff because I assume it looks more professional and to some people that matters.
You only need one tote bag, just make sure if you get a 2 stacked order and can't fit it all in 1 tote just make sure when you walk up to the customer at least their order is in a bag so they think it's fresh.
I also recommend immediately getting a second red card from the website. maybe even a third. You can't dash without one connected to your account, you can order them and have them mailed for free 1 at a time. Losing them is easy and not being able to dash is a bitch.
TECHNICAL SHIT
Pay attention to your market, whos fast and who is slow. Take a mental note of it. Are these guys slower than they are at lunch because they have long cook times and way less staff? Or are they faster because they have short wait times and no one is there? There is niche stuff that not many people are going to know the answer to like what street gets clogged during rush hour, or what restaurants are going to sling out deliveries only after they have done all their in store stuff. Did you just take a 100$ chipotle order to a preschool that tipped well? Ask the staff if they do that regularly and try to get that order every Friday.
A good formula for me is not doing anything that will make me earn less than 15$ an hour ( I honestly can't remember the last time I had a week that the average was that low ). To me there is no point in doing this job if you're just making a dollar or two above minimum wage then you're just beating up your vehicle for no reason.
5$ per delivery 1.5$ per mile 20 minutes per delivery.
These basic rules, normally nets me 15-25$ an hour. My lowest average over the last 8 weeks was 19.80. Keep in mind those are my absolute minimum requirements. I also try to keep top dasher status but that's important to me because I have trouble going to sleep at a regular time every day. Sometimes I'm in bed at 10 pm, sometimes I'm not going to sleep until 4 am. Top dasher is hard to keep and I have to break my minimum rules on the last 2 or 3 days of the month which WILL result in a lower hourly average unless you're super fucking lucky. But since it's just 2 days out of the month I take that hit, I lose 100$ a month doing it though I would guess.
top dasher is good if you're like me and really don't like having a schedule. If you do just work lunch or dinner then it is really unnecessary and bound to just piss you off.
And that's pretty much it. If anything here is confusing let me know, also to any mods reading this I am wondering if we could start a thread or directory of sorts where Specific guides for specific markets could be permalinked because not every market is the same and advice can vary from user to user. Just a thought
submitted by DasherCO to doordash [link] [comments]

[Announcement/Recruitment] Up With The Stars: A Submod For A Better Second American Civil War

The Second American Civil War is a key and classic part of Kaiserreich, but while it's hardly bad as-is, it could be a lot better. Many of us have been pointing out issues with the 2ACW for years now, but the KR devs have limited resources to make tweaks - after all, it's a total overhaul mod; there's more to it than just the USA (sorry Dougie). So it's time for a submod, tentatively titled Up With The Stars: A Better Second American Civil War
What are the problems with the 2ACW as currently implemented?
Well, for some examples:
1) The lore is dubious in many places (notably in terms of how fast the AFP and SPA have gained support) and edging on absurd in others (the right-leaning state of Indiana is under the total control of the SPA yet the more heavily unionized state of Montana isn't; there are apparently lots of syndicalists in Southern California who can...revolt and join with the Longists for unclear reasons, etc.).
2) There are many missed opportunities - The Farmer-Labor Party has no real meat to it, and you either spend 200 political power to make it be a 'party of national unity' (despite the fact that conservative Democrats would have little interest in signing up to such a deal) or it becomes irrelevant. Meanwhile, whoever is elected gets to take a whopping one focus while in the White House.
3) The set-up for the war is opaque: how does 'The [SPA/AFP] Gains Political Support' determine whether Iowa or North Carolina stay loyal to the federal government?
4) Gameplay consists of 'spam units and overrun your enemies', although this is partially a failing of the base game. Because of other aspects of the base game, this makes the CSA overpowered even with the unit caps recently implemented (incidentally, I don't care if the CSA being STRONK makes sense based on the lore, see Point #1 above).
5) Flavor seems to have been largely put together by someone not particularly familiar with interwar American history, and while hardly bad and obviously the product of much effort there are many further missed opportunities and implausible occurrences.
6) The 'revolt behind enemy lines' mechanic is rather more annoying than fun.
At the same time, the 2ACW as implemented definitely gets some stuff right:
1) The impacts of the war are felt not just in Canada, Mexico, and the Caribbean, but throughout Central and South America, and even to China, Liberia, and parts of Europe. Many countries have a chance to send volunteers and equipment to their preferred factions, making the war appropriately seem like a truly major global turning point on the way to the Second Weltkrieg.
2) The winning faction needs to take a long time to fully recover from the conflict.
3) Some of the events manage to effectively tell a story of a country spiraling into chaos and civil war, exactly the way playing the first year-and-a-bit as the USA should feel.
Drawing from, among others, the recent suggestions of u/DexterAamo, this submod will seek to keep and improve upon what works while overhauling what doesn't.
So how will this mod improve things?
Some highlights:
I think the 2ACW is fine as currently set up! This submod is a waste of time!
Great! Nobody is going to force you to download and play with this (although Douglas MacArthur WOULD like to know your location...)
This is not a small project. It is, instead, the equivalent of an official United States/Second American Civil War rework done unofficially - so high quality work will be expected both by those of us on the dev team and those playing the submod. To ensure this quality, I need help, and would like to recruit:
Previous modding experience is preferred, but not necessarily required. A tentative roadmap sees serious modding work commencing after KR 0.15 (and all subsequent hotfixes) drops, with detailed planning and preparation completed before then. A first release would then come either for 0.15.x or 0.16.x. This mod will also have innate compatibility with my Revised National Focus Times submod and will include custom country path political options.
All right, that's enough for now. Come on, loyal Americans! As you prefer: DOWN WITH THE TRAITORS, UP WITH THE STARS! Or BREAK THE CHAINS! Or AVE MACARTHUR! Or EVERY MAN A KING!
submitted by cpm4001 to Kaiserreich [link] [comments]

How to Play in Agen IDN

Agen IDN Play is one of the most popular slot machines in the world. It is located right in the heart of Omaha, Nebraska. If you are planning to play this slot machine, then there are a few important things that you need to know before you do so. First of all, this is not a conventional slot machine. It is not a real casino slot machine. Therefore, it is important that you know everything about it before you play.
First of all, Agen IDN Poker Asia is an online internet casino. In order to gain access to it, you have to become a member of that online poker site. Once you become a member, you will have access to all the games and bonuses that are offered by the site. You will also be able to play other players from around the world. Playing this online game will give you the experience of playing slots at your favorite casino without going out of your house.
Most importantly, playing Agen IDN Poker online will let you win real cash money. The jackpot amounts in this game are $8.88 million. There are also other games in which the player will get to win a cash prize. One such game is the double action bermain where you will get to play as both a banker and a dealer. This will enable you to win the jackpot in double the time!
If you want to cash out the jackpot prize, you can do so by playing the bonus new member terbosar ek, the double action double agen bonus new member terbesar and the premium bonus new member terbosar. These three games offer players an exciting chance to win real cash during their stay in the poker room. The players have to complete all the requirements before they can cash out the prize.
In order to play poker in the United States, it is essential to register at one of the many sites that provide free internet games. Such sites include the famous seven triple draw poker, the best rated five-card draw game, the famous lotto game, and the most popular game on earth known as blackjack. All these games are available for free and offer players the opportunity to play as if they were in the real casinos. Players will be able to win a cash prize from the online casinos. The players need to make sure that they play only in the approved casinos to ensure that they do not expose themselves to any risk.
To make sure that everyone gets the chance to play at the best online poker site in the country, the government of Indonesia has issued a decree that all Indonesian citizens who own or use electronic devices registered with that country's Internet service providers must use the facilities provided by the online gambling sites. This decree has also extended to those who are acting as agents for foreign companies by using their cards to sign up customers at the offshore casinos. These companies are required to abide by this law. Failure to comply could lead to serious action being taken against the company.
Playing in the United States requires that you adhere to our country's laws. In order to protect the interests of the residents of Indonesia, the regulations regarding online gambling in Indonesia have been amended. The main provision is that bonuses are only allowed for new members. Also, a new regulation allows only one bonus per player per month. Anyone who receives more than this limit will not be entitled to any bonus money.
submitted by sogijvdf to AgenIDN138 [link] [comments]

[NYTimes] Sources describe horror stories of young and inexperienced investors on Robinhood, many engaging in riskier trades at far higher volumes than at other firms

https://www.nytimes.com/2020/07/08/technology/robinhood-risky-trading.html
Richard Dobatse, a Navy medic in San Diego, dabbled infrequently in stock trading. But his behavior changed in 2017 when he signed up for Robinhood, a trading app that made buying and selling stocks simple and seemingly free.
Mr. Dobatse, now 32, said he had been charmed by Robinhood’s one-click trading, easy access to complex investment products, and features like falling confetti and emoji-filled phone notifications that made it feel like a game. After funding his account with $15,000 in credit card advances, he began spending more time on the app.
As he repeatedly lost money, Mr. Dobatse took out two $30,000 home equity loans so he could buy and sell more speculative stocks and options, hoping to pay off his debts. His account value shot above $1 million this year — but almost all of that recently disappeared. This week, his balance was $6,956.
“When he is doing his trading, he won’t want to eat,” said his wife, Tashika Dobatse, with whom he has three children. “He would have nightmares.”
Millions of young Americans have begun investing in recent years through Robinhood, which was founded in 2013 with a sales pitch of no trading fees or account minimums. The ease of trading has turned it into a cultural phenomenon and a Silicon Valley darling, with the start-up climbing to an $8.3 billion valuation. It has been one of the tech industry’s biggest growth stories in the recent market turmoil.
But at least part of Robinhood’s success appears to have been built on a Silicon Valley playbook of behavioral nudges and push notifications, which has drawn inexperienced investors into the riskiest trading, according to an analysis of industry data and legal filings, as well as interviews with nine current and former Robinhood employees and more than a dozen customers. And the more that customers engaged in such behavior, the better it was for the company, the data shows.
Thanks for reading The Times. Subscribe to The Times More than at any other retail brokerage firm, Robinhood’s users trade the riskiest products and at the fastest pace, according to an analysis of new filings from nine brokerage firms by the research firm Alphacution for The New York Times.
In the first three months of 2020, Robinhood users traded nine times as many shares as E-Trade customers, and 40 times as many shares as Charles Schwab customers, per dollar in the average customer account in the most recent quarter. They also bought and sold 88 times as many risky options contracts as Schwab customers, relative to the average account size, according to the analysis.
The more often small investors trade stocks, the worse their returns are likely to be, studies have shown. The returns are even worse when they get involved with options, research has found.
This kind of trading, where a few minutes can mean the difference between winning and losing, was particularly hazardous on Robinhood because the firm has experienced an unusual number of technology issues, public records show. Some Robinhood employees, who declined to be identified for fear of retaliation, said the company failed to provide adequate guardrails and technology to support its customers.
Those dangers came into focus last month when Alex Kearns, 20, a college student in Nebraska, killed himself after he logged into the app and saw that his balance had dropped to negative $730,000. The figure was high partly because of some incomplete trades.
“There was no intention to be assigned this much and take this much risk,” Mr. Kearns wrote in his suicide note, which a family member posted on Twitter.
Like Mr. Kearns, Robinhood’s average customer is young and lacks investing know-how. The average age is 31, the company said, and half of its customers had never invested before.
Some have visited Robinhood’s headquarters in Menlo Park, Calif., in recent years to confront the staff about their losses, said four employees who witnessed the incidents. This year, they said, the start-up installed bulletproof glass at the front entrance.
“They encourage people to go from training wheels to driving motorcycles,” Scott Smith, who tracks brokerage firms at the financial consulting firm Cerulli, said of Robinhood. “Over the long term, it’s like trying to beat the casino.”
At the core of Robinhood’s business is an incentive to encourage more trading. It does not charge fees for trading, but it is still paid more if its customers trade more.
That’s because it makes money through a complex practice known as “payment for order flow.” Each time a Robinhood customer trades, Wall Street firms actually buy or sell the shares and determine what price the customer gets. These firms pay Robinhood for the right to do this, because they then engage in a form of arbitrage by trying to buy or sell the stock for a profit over what they give the Robinhood customer.
This practice is not new, and retail brokers such as E-Trade and Schwab also do it. But Robinhood makes significantly more than they do for each stock share and options contract sent to the professional trading firms, the filings show.
For each share of stock traded, Robinhood made four to 15 times more than Schwab in the most recent quarter, according to the filings. In total, Robinhood got $18,955 from the trading firms for every dollar in the average customer account, while Schwab made $195, the Alphacution analysis shows. Industry experts said this was most likely because the trading firms believed they could score the easiest profits from Robinhood customers.
Vlad Tenev, a founder and co-chief executive of Robinhood, said in an interview that even with some of its customers losing money, young Americans risked greater losses by not investing in stocks at all. Not participating in the markets “ultimately contributed to the sort of the massive inequalities that we’re seeing in society,” he said.
Mr. Tenev said only 12 percent of the traders active on Robinhood each month used options, which allow people to bet on where the price of a specific stock will be on a specific day and multiply that by 100. He said the company had added educational content on how to invest safely.
He declined to comment on why Robinhood makes more than its competitors from the Wall Street firms. The company also declined to comment on Mr. Dobatse or provide data on its customers’ performance.
Robinhood does not force people to trade, of course. But its success at getting them do so has been highlighted internally. In June, the actor Ashton Kutcher, who has invested in Robinhood, attended one of the company’s weekly staff meetings on Zoom and celebrated its success by comparing it to gambling websites, said three people who were on the call.
Mr. Kutcher said in a statement that his comment “was not intended to be a comparison of business models nor the experience Robinhood provides its customers” and that it referred “to the current growth metrics.” He added that he was “absolutely not insinuating that Robinhood was a gambling platform.”
ImageRobinhood’s co-founders and co-chief executives, Baiju Bhatt, left, and Vlad Tenev, created the company to make investing accessible to everyone. Robinhood’s co-founders and co-chief executives, Baiju Bhatt, left, and Vlad Tenev, created the company to make investing accessible to everyone.Credit...via Reuters Robinhood was founded by Mr. Tenev and Baiju Bhatt, two children of immigrants who met at Stanford University in 2005. After teaming up on several ventures, including a high-speed trading firm, they were inspired by the Occupy Wall Street movement to create a company that would make finance more accessible, they said. They named the start-up Robinhood after the English outlaw who stole from the rich and gave to the poor.
Robinhood eliminated trading fees while most brokerage firms charged $10 or more for a trade. It also added features to make investing more like a game. New members were given a free share of stock, but only after they scratched off images that looked like a lottery ticket.
The app is simple to use. The home screen has a list of trendy stocks. If a customer touches one of them, a green button pops up with the word “trade,” skipping many of the steps that other firms require.
Robinhood initially offered only stock trading. Over time, it added options trading and margin loans, which make it possible to turbocharge investment gains — and to supersize losses.
The app advertises options with the tagline “quick, straightforward & free.” Customers who want to trade options answer just a few multiple-choice questions. Beginners are legally barred from trading options, but those who click that they have no investing experience are coached by the app on how to change the answer to “not much” experience. Then people can immediately begin trading.
Before Robinhood added options trading in 2017, Mr. Bhatt scoffed at the idea that the company was letting investors take uninformed risks.
“The best thing we can say to those people is ‘Just do it,’” he told Business Insider at the time.
In May, Robinhood said it had 13 million accounts, up from 10 million at the end of 2019. Schwab said it had 12.7 million brokerage accounts in its latest filings; E-Trade reported 5.5 million.
That growth has kept the money flowing in from venture capitalists. Sequoia Capital and New Enterprise Associates are among those that have poured $1.3 billion into Robinhood. In May, the company received a fresh $280 million.
“Robinhood has made the financial markets accessible to the masses and, in turn, revolutionized the decades-old brokerage industry,” Andrew Reed, a partner at Sequoia, said after last month’s fund-raising.
Image Robinhood shows users that its options trading is free of commissions. Robinhood shows users that its options trading is free of commissions. Mr. Tenev has said Robinhood has invested in the best technology in the industry. But the risks of trading through the app have been compounded by its tech glitches.
In 2018, Robinhood released software that accidentally reversed the direction of options trades, giving customers the opposite outcome from what they expected. Last year, it mistakenly allowed people to borrow infinite money to multiply their bets, leading to some enormous gains and losses.
Robinhood’s website has also gone down more often than those of its rivals — 47 times since March for Robinhood and 10 times for Schwab — according to a Times analysis of data from Downdetector.com, which tracks website reliability. In March, the site was down for almost two days, just as stock prices were gyrating because of the coronavirus pandemic. Robinhood’s customers were unable to make trades to blunt the damage to their accounts.
Four Robinhood employees, who declined to be identified, said the outage was rooted in issues with the company’s phone app and servers. They said the start-up had underinvested in technology and moved too quickly rather than carefully.
Mr. Tenev said he could not talk about the outage beyond a company blog post that said it was “not acceptable.” Robinhood had recently made new technology investments, he said.
Plaintiffs who have sued over the outage said Robinhood had done little to respond to their losses. Unlike other brokers, the company has no phone number for customers to call.
Mr. Dobatse suffered his biggest losses in the March outage — $860,000, his records show. Robinhood did not respond to his emails, he said, adding that he planned to take his case to financial regulators for arbitration.
“They make it so easy for people that don’t know anything about stocks,” he said. “Then you go there and you start to lose money.”
submitted by jayatum to investing [link] [comments]

Virtual Drag Race Season 13: The Reunion

Hello, Bitches.
I am Tara, your fan favourite fresh out of Asia, darlings.
Say hello to our goddess of a cast….
Miss Dearly Beloved, Haky Gardens, Damocles Nigel Dragan, Gun Anna, Creola Serpentine-Blac, Tropicana, The Aspect of Gambles, Ina Only, Pranav Tigress, Francesca Cartier, Britt-Maj Canth, Dahlia Diamondix and Our Top 3... Joan Of Snark, Omega Maddorufu and Xena Von Hall.
I'll be speaking to each Monarch about their experience in this Season.
Starting with our first out, Miss Dearly Beloved!
Dearly smiles. “Hi ya’ll.”
Now, Dearly… you were out first out and came off a liiiitlllle out of your depth. How did you feel about how you went?
“To be honest, girl. I was shocked! I thought I did decent the episode I went, and I didn’t expect to be bottom 2!” Dearly gasps.
“Girl.” Britt looks at Dearly.
“I just think I was underrated, ladies. I have more to show.” Dearly nods.
“You were FIERCE, and gone too soon.” Gun Anna nods.
“Thank you, sister.” Dearly smiles.
Now, she’s the dancing Diva, Haky Gardens!
“Hey Hey.” Haky smiles.
Now Haky, you are a fierce performer, and many said you were a robbed icon of the season. How do you feel about that?
“I feel like these Queens are LUCKY I went against one of the fiercest Queens of the season. I think I’d have won this season in any other scenario.” Haky nods.
“I agree, actually.” Tropicana smirks. “Girl is fantastic.”
“I think I realised that… it wasn’t my time, but that’s fine. I believe there is potential for me to one day become a superstar. Truly. I’m taking that crown.” Haky smirks.
I look forward to seeing it.
Now, he shocked us all when he broke his leg during a lip sync for his life. Damocles Nigel Dragan…
“It’s me.” Damocles smiles.
When it all happened, it shocked the world… how are you feeling now?
“I am still recovering. It’s been hard but there are a lot of rumours going on… I am not in the headspace for competition like this, I think I’ve realised. It’s not healthy for me.” Damocles nods.
“I think that’s important.” Omega nods. “Knowing sometimes when to be like… no. I can’t do that.”
“I’m going to be okay in the end. I have fans, and I’ve been able to further my drag even more. Even if it’s avoiding dancing.” Damocles smiles.
Now, she was.. Controversial this season. For a variety of reasons. It’s-
“I am no longer Gun Anna.” Anna smiles.
Oh, wow.
Who… are you now?
“Anna.” Anna smiles. “I haven’t talked to you all besides… Dearly. But I want to say this. I’ve educated myself, I’ve developed… and I’ve worked on myself significantly since my season. My values, my opinions and… perspectives has always been different, and now I know it comes from a lack of education. I know a lot more. So… I’m a left wing, antifa drag queen now.”
“I think that’s great.” Britt nods. “But the only thing I’d say is… don’t just run to another group. Educate yourself, Bourgeois Anna.”
Anna nods. “I will.” Anna smirks. “I do like the sound of Bourgeois Anna…”
Now, she was a stunning Queen from the Haus of Serpentine-Blac….
“It’s Creola.” Creola winks.
You had a moment with Tropicana early in the season, feuding over some… drama. How are you two now?”
“We’re…” Creola looks at Tropicana. “We’re good.”
“I think we had our moment, we had our drama but it all worked out in the end. She’s fierce, I'm fierce.” Tropicana grins. “So…”
“I think it was good to have that moment. It patched things out. It was needed.” Creola nods.
On the topic of Tropicana…
Tropicana raises her hands in the air.
How are you now, with your Haus of Juice family?
“We’re back together.” Tropicana smiles. “I’ve learnt… a lot this season. I think I did really good, but that moment, that makeover? It was probably the most important.”
“That should’ve been a solo lip sync, and you shouldn’t have gone snatch game.” Pranav nods.
“100%.” Gambles smirks. “100 fucking percent.”
Franesca purses her lips.
Now, he was the strongly worded magician of the season. The Aspect of Gambles.
“Meeeeeeeeeeeee!” Gambles laughs.
How pissed were you about missing the magic challenge?
“Oh, I was mad.” Gambles laughs. “I’d have SLAYED that challenge.”
“I honestly think Gambles was a highlight of this season.” Joan smiles. “He had so much potential so… I was surprised he didn’t win a single challenge.”
“I for one was happy with Gambles to go.” Britt smirks. “He was a threat.”
“Nasty.” Gambles laughs. “I think I just… wish I had those damned sewing skill. Something I am working on for sure.”
“Is that a hint?” Pranav looks at Gambles.
“No, no…” Gambles shrugs. “Just saying!”
Now, the fans GAGGED when she was shockingly eliminated, our Dragula Icon, Ina Only!
“Dragula Icon.” Ina laughs.
Now, you were expected to be a frontrunner, and you won our first episode. What happened?
“I think I let the nerves get the best of me. As people were getting more and more into it… I faded and let myself not hit the mark. I just didn’t meet the mark, and I flopped the lip sync.” Ina sighs.
“But like Ina…” Tropicana nods. “She’s fantastic regardless. I think she has the skills to make it to the end, so I was surprised.”
“I am excited to prove myself in future. I know I have the skills, I just… lost the grip a bit instead of actually… gripping tighter.” Ina nods.
Now, he was the King of Tigress’s and he’s had… an interesting run. It’s Pranav Tigress!
Pranav nods. “Interesting for sure.”
You were kind of… a man against the world on your season. How did you feel, watching it back?
“I felt vindicated.” Pranav nods. “I was right. I knew I was right. And it was clear.” Pranav looks at Francesca.
“That’s not true.” Francesca nods. “I-”
“Don’t even try.” Dahlia looks at Francesca.
Pranav grins.
“I just want to say… I am sorry.” Omega nods. “We didn’t listen to you.”
“I feel bad.” Xena nods. “You were clearly speaking at a brick wall. It was… not good. I think we as a group needed to be more open and honest and listen.”
“It’s okay.” Pranav nods. “I just… feel happy it was seen.”
On that Topic… She's had many controversial moments this season. Franesca Cartier… how are you?
“I am… well.” Franesca nods.
How do you feel about your role in this season?
“I think it was clear this season, I wasn’t a supervillain. I was simply-”
“Okay, you KNOW how to play the role of a nice person.” Dahlia exhales. “And the fact you are a LIAR…”
“A big fucking liar.” Creola nods.
“Was fucked. You hurt a number of people this season, emotionally and physically.” Dahlia furrows her brow. “You hurt people.”
“I just don’t get the WHY?” Gambles shrugs. “Why the fuck you gotta do that.”
“I didn’t do anything.” Francesca shrugs. “When you look at the shows-”
“Okay, we just said that though.” Britt begins to clap. “You. Were. Playing. A. Role.”
“I don’t need this.” Francesca shrugs. “I was here to defend myself, and now I’ve done that…” She smiles. “Bye.”
Francesca walks off.
I’m not going to bring back anyone. She can stay gone.
“Just own it.” Xena sighs. “Own your attitude.”
“Be authentic. She isn't.” Tropicana shrugs.
Now, the late stage swedish fish. Britt-Maj Canth!
“Hello.” Britt smirks.
Now, you had an interesting run. You always had an opinion.
“I did.” Britt nods. “I think giving feedback is valuable. It’s important. At times, did I step boundaries? Perhaps, I gave too much feedback. But that is me.”
Damocles Nigel Dragan, Gun Anna, Creola Serpentine-Blac, Tropicana, The Aspect of Gambles, Ina Only, Pranav Tigress, Francesca Cartier, Britt-Maj Canth, Dahlia Diamondix and Our Top 3... Joan Of Snark, Omega Maddorufu and Xena Von Hall.
“And that’s the difference.” Pranav nods. “Britt can be shady, but she says the truth, and she’s always authentic. Francesca was nothing like that.”
“And now, she’s gone, and this room feels a lot lighter.” Ina nods.
And Finally, our youngest Queen of the season, Miss Dahlia Diamondix!
“Woohoo!” Dahlia smiles.
You probably had the biggest growth and development of this season. How did you feel about it all? Where are you now?
“I am… in a location.” Dahlia nods. “I’ve stepped up my drag, and moved cities.”
Where are you now?
“Nebraska.” Dahlia smirks.
Does that mean…?
“I’m getting my wings. They’ll be here… soon. That’s all i’ll say.” Dahlia smirks.
“I’m really proud of Dahlia.” Joan nods. “She I think developed tenfold, so this? Seems perfect…” Joan grins. “Well deserved.”
“Agreed.” Britt smiles.
Now, before we conclude our little reunion… I have to ask our eliminated Monarch’s. Who do you want to win? Starting with Dearly.
“Oh of course Xena. EXCELLENCE.” Dearly smiles.
“Xena is that flair. That Pristine Perfection.” Haky smiles.
“I gotta give it Joan. She excites me.” Damo nods.
“I think Omega is a nice, loving person who deserves this.” Anna looks at Omega and grins.
“I think Xena. Really fierce. So Xena.” Creola smirks.
“I love Omega. He brings something different to this circle.” Tropicana nods.
“Fuck this is hard.” Gambles laughs. “Joan.”
“I think Omega deserves this.” Ina smiles.
“I also think Omega. Someone who… always tried hard for others.” Pranav nods.
“I’m voting Xena, of course.” Britt grins.
“Omega.” Dahlia blushes. “You deserve it.”
And that’s been the SEASON 13 REUNION!
Coming up… one of our final 3… Will be given their… Crown.
~
Spreadsheet
submitted by AustralianChrono to RPDRfantasyseason [link] [comments]

Defending the Draft: San Francisco 49ers

Defending the 49ers Draft
The 2019 49ers were not expected to be much at the beginning of the season. If a 49er fan told you at the beginning of the 100th year season that the 49ers would not only go 13-3 and get the first seed but also make the Superbowl, you’d tell them to put down the crack pipe and stop being a massive homer. That’s how badly the 49ers have been the past few seasons. With a record of 2-14,6-10, 4-12 the past 3 years, one could hardly blame you for laughing at someone for thinking that the 49ers would be Super Bowl Contenders. Make the playoffs? Sure, why not. Win the division? Plausible, but unlikely considering you had the Super Bowl Appearing Rams and the ever-dangerous Seahawks with Russell Wilson to deal with after all. Make the Super Bowl pfft yeah right. But somehow this crack dream became a reality for 49ers fans. The 2019 49ers would not only be good--they’d be elite. With an elite defensive Line consisting of 4 First round D-lineman, and a creative offense orchestrated by offensive genius Kyle Shanahan, the 2019 49ers were a force to be reckoned with. Barely falling to the Kansas City Chiefs in Super Bowl LV. So, with that the 2020 49ers expectations were higher than their 2019 variation. Here’s what John Lynch and Kyle Shanahan (ShanaLynch) have done so far to try and live up to them.
Offseason:
Key Loses: Emmanuel Sanders (WR); Deforest Buckner(DT), Trade for Colts 2019 First Round Pick; Joe Staley (LT), retirement; Mike Person (OG), Cut
Free Agency Additions: Travis Benjamin (WR); Tom Compton (OG); Joe Walker (LB)
As defending NFC Champions, the 49ers didn’t have many big moves that they could make due to being close to the cap, the need to retain key free agents and the contract extension of superstar Tight End George Kittle. Comparing the loses to the gains we can safely say the losses list is far more memorable than what they gained in free agency. Therefore, the main plan for the 2020 offseason was retaining as many players as possible. They were able to re-sign key pieces like Arik Armstead and Jimmie Ward, who were two valuable starters of the 49ers defense. Sadly, contract extension negotiations with Deforest Buckner didn’t go as the 49ers had hoped, and the 49ers traded him to the Indianapolis Colts for the 13th Overall Pick. Mid-season acquisition Emmanuel Sanders decided to walk from the 49ers contract offer and instead go to the New Orleans Saints. Starting Guard Mike Person was cut. Long time left tackle Joe Staley retired (that will be talked about later). The 9ers got some additions through free agency, but they are unlikely to make a significant impact on the team. With an offseason highlighted by loses, it was clear that the 49ers would need to look to the NFL draft if they wanted to improve upon their 2019-20 season.
Day 1:
The 49ers had Two Picks in the first round, setting them up for the potential of a very busy day one. Depending on what ShanaLynch wanted to do they had plenty of options available on what to do with these two valuable picks. Here’s what they decided to do with them.
Lead up
Originally having the 13th overall pick at the time, the 49ers had a plethora of options at this pick. Many mock drafters and 49ers fans themselves expected the 49ers to go with one of the big 3 of the wide receiver class (Jeudy, Lamb, and Ruggs). At the time of the pick there was still two of the top receiver prospects on the board and one of the top tackles of the class left in the class in Tristan Wirfs. Instead of picking them ShanaLynch decided to trade down and gain some draft capital. They ended up trading down with Tampa Bay only one spot and gained a 2019 4th in exchange for a 2019 7th. When the time came for them to pick again instead of the top receivers left here’s who they decided to pick.
Round 1 Pick 14: Javon Kinlaw, Defensive Tackle, South Carolina
If you were to ask an NFL fan, “what is the scariest thing about facing the 49ers?”, the thing that will come up most is “man, they have a scary defensive line”. Buckner played a vital role, and his trade sent the 49ers D-line from “cheat code” to just top 5. If the 49ers wanted to keep up their defensive line dominance than they would need a monster to replace Buckner. Javon Kinlaw is a monster. At 6’5” 324 lbs with long arms, Kinlaw is a freak of nature that can eat up double teams and straight up win one on ones. When watching his tape, one consistent thing is the power he plays with. Against Georgia he completely dominated that game, playing almost every snap, and was consistently in the face of Jake Fromm, even directly causing Fromm to throw a crucial pick 6. In the Senior Bowl he was completely dominant and almost no one was able to stop him. When they play against the 49ers, NFL Qbs will now have the unpleasant option of either being pushed out of the pockets and into the arms of Bosa and Ford, or stepping up into the pocket of Kinlaw and Armstead. The ability to be able to create pressure by rushing 4 is a nightmare for QBs. On passing downs this season 49ers opponents will have to choose to double either Bosa, Armstead, Ford, or Kinlaw or keeping eligible receivers in the backfield to help block. Most teams will undoubtedly choose to leave the rookie one on one and if Kinlaw translates his college game to the nfl, that will likely be the wrong choice.
His big knock predraft was his lack of technique and his reliance on power. Even Kinlaw himself admitted that he needed to get better with his technique. To reach his full potential, Kinlaw needed a good D-line coach—conveniently, 49ers Coach Kris Kocurek is one of the best in the business. With a resume consisting of Ndamukuh Suh, Ezekiel Ansah, Cameron Wake, Robert Quinn, and the 2019 49ers, Kocurek has helped coach and develop a lot of talented D-Linemen. Kinlaw is in the right hands and if he busts it won’t be due to his environment on the 49ers.
Some people may say “it was a bad move to trade Deforest Buckner only to replace him with someone you hoped could be as good as him. It may have been better to just accept d-line weaker and upgrade something else like wideout. The d-line will still be good but the wideouts will be better.” It’s a reasonable argument to make and one of the reasons why I was initially hesitant about the Kinlaw pick. But one could argue it wasn’t just Deforest Buckner for Javon Kinlaw, but it was Deforest Buckner for his replacement and cap flexibility. If the 49ers wanted to maintain cap flexibility, they had a choice of Buckner and at best a 2021 3rd round comp pick from losing Armstead or Armstead and Kinlaw. It’s a hard choice to make, but if Kinlaw works out it becomes the easy choice, and Kinlaw is a very good prospect to make that bet on.
Lead up
With their original first round pick many pundits anticipated that the 49ers trade back. They had no day 2 picks and only had a 4th, two 5ths, a 6th and a 7th. Many analysts and experts expected the 49ers to fix the lack of day 2 picks with pick 31. It makes sense, get an elite prospect with their early pick and use their later first rounder for more picks. When it comes to the drafts, Analysts usually prefer to go for a “quantity over quality”-type approach--get as many players as possible and hope at least one of them works out. The 49ers traded the pick all right… It just wasn’t down. With their 2020 first rounder along with their 2020 4th they got from the trade down from thirteen and a 2020 5th, the 49ers traded UP with the Vikings to gain pick 25. I was shocked by this trade, as most 49ers fans were. We were expecting a trade down. By trading up, the 49ers completely obliterated any hope of having a day 2 pick and basically decimated the rest of their draft capital. In short, this trade up was a huge gamble. It was obvious that the 49ers were going to take someone who they were all-in on. So, who’s this player that the 49ers blew the rest of their draft capital load on?
Round 1 Pick 25: Brandon Aiyuk, Wider Receiver, Arizona State
After a season with inconsistent wide receivers, it seemed very likely that the 49ers would take a receiver with one of their first-round picks. Most fans and analysts figured it would be Jeudy, Ruggs or Lamb at 13 and then trade down with their other pick. By trading the 13th pick, and picking Kinlaw at 14, Shanahan showed that he wasn’t interested in any of them. Instead he went with Aiyuk, a player with a first-round grade but not mentioned as much by most fans. Shanahan, however, after the draft, called him his favorite receiver in the draft. Normally one could say this is just coach speak, but if you look at his tape and the traits he has, it’s very plausible that Aiyuk was Shanahan’s first choice. This one is going to be a long, and the reason it’s going to be long is because I believe Aiyuk is going to be the key pick for this draft. If Kinlaw doesn’t work out its bad but our defensive line is still going to be fine. Aiyuk on the hand can make or break our wide receiver room, outside of Deebo there are a lot of question marks and with the fact we spent what little draft capital left we had on him, there’s a lot invested. I’m going to be honest here, I didn’t really investigate Aiyuk that much. I was sure that the 49ers would go with the big 3. I was dead wrong on that. Looking at him now my thoughts on him are “man he is damn good”. At 5’11 3/4th” and about 200 pounds one of the most noticeable things about him is his wingspan--81 INCHES. To quote u/rockysauce115 “That man can tie his shoes standing up”. The one thing he stands out for among what is considered one of the deepest wide receiver class is something that has become synonymous with the 49ers themselves, YAC. Aiyuk averaged 18.3 YPR and of those yards 9.9 of them were after the catch leading the nation. Once the ball gets in his hand he doesn’t go down, no he keeps moving and if defenders fail at making a play he is gone.
At the combine he ran a 4.5 40--a decent score, but nothing to special. Aiyuk was still recovering from a core muscle surgery, however, and if you put him on tape and his highlights you realize he runs on the field faster than his 40. He absolutely can dust guys. Last season he was marked at running 21.97 mph in pads. To put that in context, only three other players in the Nfl ran faster. Take that what you will but just know that Brandon Aiyuk is a lot faster than his 40 time--make a mistake and he has enough speed to make you pay for it. His burst, however, is elite. Having a 40 inch vertical jump and a 128 inch Broad Jump translates him to a Burst score of 132 (92nd Percentile). This man is not just a workout warrior but an athlete, and that translates on the field. Aiyuk can work magic once the ball is in his hands. Now the question becomes, “will it be possible to get the ball into his hands at the NFL level?” The short answer is “yes”. Shanahan has a penchant for getting receivers open in the NFL. If he wants Aiyuk to have the ball, he will get Aiyuk open enough to get the ball. But even if he didn’t have Shanahan scheming him open, I believe Aiyuk would be able to get open on his own in the NFL. Brandon Aiyuk doesn’t have the route running of Jerry Jeudy--no one does. But when you put on his tape you can see that despite his need to polish his route running, he has a solid foundation that teams can build on. His feet are light. They aren’t clunky and they can change direction in an instant. He has shown the ability to set up corners. These things make him a prospect that Shanahan can mold into the receiver he needs to unlock the full potential of his offense. Who is the receiving coach that will be tasked with helping Aiyuk get there? A guy who knows a thing or two about route running—Wes Welker.
Criticisms/concerns surrounding Aiyuk are 1) being just a one-year wonder, 2) his competition in the PAC 12, and 3) the trade up itself. Aiyuk isn’t a typical one-year wonder like most people think. He was a beast in Junior College being named a junior college All American his sophomore year and while it doesn’t mean much it does show that he was able to dominate his lower competition which you want to see out of elite guys . Junior year the argument can be made that he was adjusting to the FBS level and when he finally got the chance to be the number one in Arizona State’s offense his senior year, he made use of that opportunity and ran away with it like he ran away from defenders. The one-year wonder is a valid concern but I don’t think its back breaking. He’s always been good he just hasn’t been good on the highest stage yet.
The Pac 12 was not good, it hasn’t been for a while. When Aiyuk faced good defenses he generally did not produce. The only one he did was against Oregon and man did he leave a mark on them. But his supporting cast also wasn’t the greatest. For example, he had Jayden Daniels at Qb… Jayden Daniels was ranked the worst pac 12 qb in terms of accuracy and PFF had him graded as the 72 ranked Qb in the FBS. No knock-on Daniels--he was only a freshman and he will probably get better, but for Aiyuk, he was terrible. So yes, one can argue that Aiyuk didn’t face the best competition but the counter to that is it’s not like his team mates were world beaters either and somethings were out of Aiyuk’s control and all he can do is put his best on tape and generally his best was really good.
Finally, the trade up, a lot of pundits have been saying “you didn’t need to trade up for him he would’ve been there at pick 31 heck you could’ve traded down and still gotten him.” That’s bogus YOU don’t know if he will be there at pick 31 all it takes is one team that is ahead of you that rates him as similar as you do and suddenly your guy… gone, instead you have to settle. Now you can make the argument that they should’ve just settled and get one of the second-round receivers after all this is one of the deepest draft classes in a while. Buuuttt looking at the second round wideouts none of them really seem like they’d be as good of a fit for the 49ers. So even if they stayed put and settled, there didn’t seem to be a receiver that fit Shanahans offense as well as Aiyuk did. Its scheme fit vs talent and when that Scheme fit also has talent it apparently was too much for Shanahan too miss out on and he needed to trade up for him.
When we initially picked Kinlaw I was bummed, he was a good player but I was hoping to add a receiver that can add another dimension to the offense. Looking at the Aiyuk tape now it makes me feel a whole lot better about the Kinlaw pick. I really like Aiyuk and the potential he has and I’m excited to see him in the Shanahan offense. I think the 49ers are lucky that they were able to get a prospect like him at pick 25. In a year not as stacked at wide receiver he very well could’ve been a top 3 wide receiver. Either way the 49ers got a very good wide receiver prospect and I’m hopeful and believe he can do great things for them.
Day 2:
The 49ers didn’t have any day 2 picks and the reason for this is because they traded them for immediate contributors. The 2020 2nd round pick was used for Dee Ford and the 3rd and 4th round pick were used for Emmanuel Sanders. I’ve seen worse use of day two picks and even though Sanders was a half season rental he provided a stability and veteran presence that was desperately needed in the wide receiver room.
Day 3:
Day 3 was a big day. Leading up to the draft there were rumors of Longtime 49ers left tackle Joe Staley retiring and these rumors were true. Staley has been a rock for years and it will be sad to no longer see him on the line. With his retirement the 49ers NEEDED a left tackle, now they could’ve done the safe thing and just take Wirfs at 13 and just live with the fact that they would no longer have a dominant defensive line, instead they chose to go a different route. With a 2020 5th round pick and 2021 3rd round pick the 49ers acquired Trent Williams from the Washington Redskins. I really don’t need to defend Trent Williams since he’s literally the perfect Shanahan Tackle--big, athletic, and moves way faster than a man his size should move. He’s earned quite a few pro bowls, and people know who he is. Normally it would’ve cost quite a bit to get tackle of his caliber but due to drama in Washington the 49ers were able to get him for cheap. If he can shake off the rust from missing a year, Jimmy G’s beautiful face won’t ever have to worry about his blindside. Hopefully they can re-sign him to a reasonable contract but if they don’t a 3rd and a 5th is still a good price for a guy his caliber even if it’s for one year. I love Joe Staley and he had an amazing career, but for 2020 I’d bet that a 32-year-old Williams is going to be an upgrade over a 35-year-old Staley.
Lead up
Fan favorite Rb Matt Breida was traded to help the 49ers gain some draft capital back and he was traded to the dolphins for their pick. He was great value; a UDFA, became a key contributor and was flipped for a 5th rounder. Here’s his replacement
Round 5 pick 153: Colton Mckivitz, Offensive Tackle, West Viriginia
Mckivitz was a 4-year starter at West Virginia and played both right and left tackle. He was always on the field for them and was just a mean guy that can move people. Many pundits expect him to move inside and he will have the chance to win the now vacant RG spot. You should never complain about offensive line depth and if he wins the starting guard job this is a fantastic pick—that, or our guards suck. If all he does is be depth on the line and fill in where he can that’s still great and a good use of a 5th rounder. Something that is interesting is that he earned first team All big 12, big 12 co-offensive lineman of the year and an 2nd team All American. The reason that’s interesting is that generally offensive linemen awards usually just go to guys on good teams. West Virginia was not a good team, and the fact that he was able to earn those rewards shows his ability.
Lead up
Their 6th round pick involved a trade up with the Eagles. The 49ers didn’t give up much and all it was worth was Marquise Goodwin. Goes to show how much Goodwin was worth to the 49ers. But with the pick swap here’s who they moved up for that they thought was worth one Marquise Goodwin.
Round 6 pick 190 Charlier Woerner, Tight End, Georgia
Charlie Woerner is a 6’5” 252 pound Tight end that really wasn’t involved in the passing game that much. He’s an athletic dude but a bit slow and he didn’t have very much production in terms of receptions and frankly he’s not really projected to be much in the passing game. So why was this guy drafted? Well this man can BLOCK and he blocks well with energy and enthusiasm. This guy can wall off defenders and if he’s in space he can help spring the running backs into big gains. He’s going to be the Levine Toilolo replacement, a blocking tight end that can help the run game. If he has any impact in the pass game it’ll be extra, but if you’re a tight end and you’re willing and able to block you will find out that teams can find roster spots for you.
Lead up
The 49ers made a lot of moves in the draft and with their last pick it was the only original one that didn’t trade. So here’s the last pick of the 2020 49ers draft Class.
Round 7 pick 217: Juan Jennings, Wide Receiver, Tennessee
The first thing that I can think of when I put on his highlights is “man this kid plays tough”. At 6’3” and 210 pounds he’s a big slot that makes plays every time the ball is thrown his way. You can see the heart he plays with and I can see why Tennessee fans love him. Sadly, he is a bit slow, running a 4.72 which is not good for a wide receiver. But he makes plays with the ball and he is a tough receiver. As I look at him though, I’m sorry Tennessee fans, he’s most likely just Jalen Hurd insurance. He has a similar profile to Hurd but Hurd is more athletic. Jennings has a bit of climb to make the 53-man roster. Granted if Hurd fails to comeback or even busts, I think Jennings can fill the role that Shanahan hoped Hurd can fill in a big receiver that can play multiple positions and make plays with the ball in hand. For a team there’s nothing wrong with getting insurance in case a certain part you want doesn’t work. It sucks for Jennings but if he does well in camp but gets cut due to no room I won’t be surprised if another team immediately picks him up.
UDFA
Despite the draft being done there still was guys that can make an impact that didn’t get drafted. So with that here are some interesting 49ers UDFA
UDFA Jamychal Hasty, Running Back, Baylor
Shanahan is known for crapping out production from no names at running back. All he needs is a guy that can one cut and be fast. Jamychal Hasty can one cut and be fast, he is an Athlete with burst and speed. He will probably replace fan favorite Matt Breida in being that speedster. He also did make some plays in the passing game at Baylor and if he can do that in the NFL as well that’d be great.
UDFA Chris Finke, Wide Receiver, Notre Dame
Chris Finke is your stereo typical white slot receiver. He can run routes well and make tough plays over the middle. A real gym rat, a last guy out first guy in type guy. Jokes aside I personally think he’s Trent Taylor insurance, a guy that can just get open at the sticks and be an option for Jimmy G on third downs but if he ends up more, well, nice.
UDFA Darrion Daniels, Defensive Tackle, Nebraska
Daniels is a big dude who can hold his ground on the line of scrimmage. He doesn’t offer much in the pass rush but in the run game he can take double teams well. If he can be a great Run defender and be D-line depth it’s a good signing.
Conclusion
The 49ers in this draft went the opposite of what analytics wanted--they decided that they would rather go for quality of prospects than quantity of prospects. The front office mentioned that the reason that they weren’t that desperate for mid round picks was because they felt the roster was well set and it would be harder for those mid round picks to make the team. Heck--out of the 22 starters last year’s super bowl appearing, 19 of them will be returning. So, it's reasonable to think that there’s not much room. Instead of the shotgun approach to the draft they are hitching this drafts success in Brandon Aiyuk, Javon Kinlaw and Trent Williams (even though Williams is not a rookie). It’s not a bad set of names to bet on and they did the best they could over the offseason to try to run the table again. I’m excited to see these new names and how they’ll fit, and I’m also excited to see what new fun plays that Shanahan will reveal.
53 Man Roster prediction
QB: Jimmy Garoppolo, Nick Mullens, CJ Beathard
RB: Raheem Mostert, Kyle Juszcsyk, Tevin Coleman, Jerrick Mckinnon
WR: Deebo Samuel, Kendrick Bourne, Brandon Aiyuk, Trent Taylor, Jalen Hurd, Dante Pettis
TE: George Kittle, Charlie Woerner. Ross Dwelley
OL: Trent Williams, Laken Tomlinson, Weston Richburg, Daniel Brunskill, Mike Mcglinchey, Justin Skule, Shone Coleman, Ben Garland, Colton Mckivitz
DL: Arik Armstead, Javon Kinlaw, DJ Jones, Nick Bosa, Dee Ford, Solomon Thomas, Kentavious Street, Ronald Blair, Darrion Daniels, Kerry Hyder
LB: Fred Warner, Kwon Alexander, Dre Greenlaw, Azeez Al Shaair, Jonas Grififn
CB: Richard Sherman, Emmanuel Moseley, Kwaun Williams, Akhello Witherspoon, Tim Harris, DJ Reed
Safety: Jimmie Ward, Jacquiski Tartt, Tarvarius Moore, Marcell Harris
Specialist: LS, Kyle Nelson; K, Robbie Gould; P, Mitch Wishnowsky
submitted by ghostofabhelmet to NFL_Draft [link] [comments]

can you gamble in nebraska video

YouTube Can You Afford To Gamble On Your Goals (+ Winstar Casino ... Spanish Gamble - 5 Things Amish Women Don’t Want You To Know - YouTube Black Light Experiment Shows How Quickly COVID-19 Can ... 15914 Middle Island Dr, South Bend Nebraska - YouTube Can you feel it? Nebraska vs. Wisconsin - YouTube Nebraska retiree uses earths's heat to grow oranges in ... Nebraska Cornhusker Football 2013 Spring Game - Can You ...

Nebraska has 20 casinos in which you'll find more than 899 slots and gaming machines. Click a casino on the left for more information on a particular property. If you wish to stay at some nice casino hotels in Nebraska, visit the Nebraska casino hotels page. We actually have 0 Nebraska hotels you can book directly from World Casino Directory. A: The Nebraska State Constitution (Article III, Section 24) is the base to determine what forms of gambling are permitted or prohibited. Until 1934 ALL forms of gambling were illegal. At that time the Constitution was amended to permit pari-mutuel horse racing when conducted on licensed race track enclosures. First, the gambling ages - these are important. You can't gamble if you aren't of the legal age, and Nebraska has some interesting requirements. The 2021 Nebraska legal gambling age depends on what you’re trying to wager on. The age of 18 only opens you up to bingo. You still have to be 19 to hit the racetracks or play the lottery. Nebraska is a regional outlier when it comes to gambling, as the local laws are much more stringent than in neighboring Iowa, South Dakota, or Kansas. Legal gambling options in the Cornhusker State are limited to horse race betting (legalized in 1934, off-track betting introduced in 1988), bingo (1958), keno (1985), and lottery games (1992). … Minimum Age to Gamble in United States of America Below you will find the minimum legal age to gamble in various locations around the U.S., Virgin Islands and Puerto Rico. In the 50 American states, some times you'll see a variance, this usually is due to Indian casinos having different age requirements in their casinos than state regulated casinos. If you have questions about the harms of gambling or any other topics, you can send me an email at [email protected] or call 402-471-2244. Pete Ricketts is the governor of Nebraska. Ricketts As discussed earlier, Nebraska’s minimum gambling age varies per available gambling option. 18-year-olds can engage in charitable gambling which includes, lotteries, bingo, raffles, pickle cards, and keno. Patrons must be 19 to purchase any state or multi-state lotteries, or play keno. Do you gamble? Health Alert: A side effect of a carefully designed gambling system is getting you into “the zone” of long, uninterrupted gambling. From ergonomic chairs that ease you into longer play sessions to pop culture-themed slot machines delivering 1,200 plays an hour — every element of the gambling system is a careful design that mesmerizes the person gambling, moving them into a In most states you have to be either 18 or 21 to gamble for real money.Today there are 22 states where 18-year olds can legally gamble and 35 which only allow 21+.

can you gamble in nebraska top

[index] [9219] [8911] [156] [5643] [5724] [9696] [8760] [6691] [8421] [2504]

YouTube

Spanish Gamble (Paper+Plastick Records) from Gainesville, Florida performing 'Can I Live?' from their album 'It's All Coming Down' at Mucky Mulligans in Pert... Beginning of game can you feel it plays and all the way up till tip off Can You Afford To Gamble On Your Goals - It's one thing to take risks in your business...it's quite another to go 'all in' on something so speculative (whate... 5 Things Amish Women Don’t Want You To Know Enter to win 4 tshirts here: https://gleam.io/competitions/mD0w7-giveaway-1🔶Follow us on Twitter: https://twitt... Winter temperatures in Alliance, Nebraska can drop to -20°F (the record low is -40°F/C), but retired mailman Russ Finch grows oranges in his backyard greenho... This video was uploaded from an Android phone. Sorry for the refresh rate of the Jumbo Tron...hope it isnt too distracting. Always dreamed of living on an island? Now you CAN. This stunning 3 bed 2.5 bath is paradise on earth in South Bend. Stone finishes throughout, designer cabi... Enjoy the videos and music you love, upload original content, and share it all with friends, family, and the world on YouTube. This black light experiment shows how easily a virus like the coronavirus can spread in public.» Subscribe to NowThis: http://go.nowth.is/News_Subscribe» Sig... Video Poker instruction from casino author/expert Steve Bourie that teaches you the details on how video poker machines work and how to be a long-term winner...

can you gamble in nebraska

Copyright © 2024 top.onlinerealmoneybestgames.xyz